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ABSTRACT OF DISSERTATION

Host-Parasite Interaction in Horses: Mucosal Responses to Naturally Acquired
Cyathostomin Infections and Anthelmintic Treatment.

Cyathostomins are ubiquitous parasites in equids. In rare cases, cyathostomins lead to a
generalized typhlocolitis and death. In healthy horses, local reactions are noted to the
mucosal larvae; however, the mechanisms and importance of these reactions have not
been elucidated. It has been hypothesized that anthelmintics can alter these reactions.
Currently, three drug classes are approved for use in horses against cyathostomins; while
all products target the adults, only two products are labeled as larvicidal. Adulticidal
therapy is implicated in triggering the typhlocolitis, however, current evidence is
contradictory. There is also conjecture that the larvicidal drugs can increase the risk for
adverse inflammatory reactions; however, there has been limited investigation into
possible mechanisms. One component of the local mucosal response is goblet cell
hyperplasia (GCH), but its exact role in cyathostomin infections is unknown. We
hypothesize that GCH in horses plays an important role with expulsion of the worms
following treatment.
Two studies were conducted to elucidate the local and systemic immune response
following larvicidal treatment based on histology, immunohistochemistry, and gene
expression. In the first study, ponies with naturally acquired cyathostomin infections
were allocated into three groups: fenbendazole-treated (FBZ), moxidectin-treated
(MOX), and untreated control. Whole blood was collected weekly and tissue samples
from the large intestine were collected at the 2- and 5-weeks post treatment (WPT)
necropsies. Samples were evaluated for proinflammatory, anti-inflammatory and local
mucosal responses. There were few significant differences between the three groups;
however, there were significant correlations between luminal worm burdens, GCH, and
goblet cell gene expression (MUC2, r= -0.2358 and RELM-β, r= -0.2261). This study
identified the potential for seasonal turnover and expulsion of worms, where GCH score
was lower at 2 WPT than 5 WPT across all groups (p<0.001), and not associated with
treatment.
The second study aimed at evaluating and comparing a larvicidal treatment with a nonlarvicidal treatment belonging to the same anthelmintic class to classify the local and
systemic immune response following larvicidal treatment based on histology,
immunohistochemistry, and gene expression. Horses with naturally acquired
cyathostomin infections were allocated into three groups: Ivermectin (IVM)/praziquantel-

treated, MOX/praziquantel-treated, and untreated control. Whole blood was collected
weekly and tissue samples from the large intestine were collected at the 2 and 5 WPT
necropsies. Samples were evaluated for proinflammatory, anti-inflammatory and local
mucosal responses, as above. MOX treatment was associated with lower GCH than the
control and IVM treatment groups, and the IVM treated group had lower GCH than the
control horses (p<0.0376). There were statistically significant positive associations
between mucosal worm burdens and goblet cell hyperplasia and associated gene
expression (GCH scores p<0.001, MUC2 p<0.001, RELM- β <0.001). Higher GCH was
associated with higher worm burdens across all groups and was higher at 2 WPT than 5
WPT.
Overall, these studies demonstrate that treatment with an anthelmintic, both larvicidal and
non-larvicidal, in healthy horses does not significantly change the proinflammatory or
anti-inflammatory response. In fact, it may decrease the local mucosal response in horses,
due to the decrease in worm burdens. Cyathostomins induce a proinflammatory response
within the host tissue, while the encysted larvae may also induce an anti-inflammatory
response as well. These studies demonstrate that that GCH is implicated in worm
expulsion. This could further impact what we know of infections and how we interpret
the disease complex.

KEYWORDS: Cyathostomin, Equine, Goblet Cell, Host-Parasite Interaction,
Anthelmintic treatment, Mucus.
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CHAPTER 1. LITERATURE REVIEW
1.1

Parasites of Equids
Domestic horses (Equus ferus caballus) are hosts to one of the most diverse parasite

populations in the animal kingdom (Lichtenfels et al., 2008). Of the kingdom Animalia, 3
phyla parasitize horses: Arthropoda, Nematoda, and Platyhelminthes. This literature
review will focus primarily on the Nematoda and one platyhelminth that infect the
gastrointestinal tract of horses, to allow for greater focus. When discussing the following
classifications, phyla, classes, orders, suborders, and genera will be discussed as presented
in Georgis’ Parasitology for Veterinarians 10th edition (Bowman, 2014).
1.1.1 Anoplocephalids
In the phylum Platyhelminthes, lies the family Anoplocephalidae. Within this
family, there are three species, which infect the gastrointestinal tract of horses,
Anoplocephaloides mamillana, Anoplocephala magna, and Anoplocephala perfoliata. A.
mamillana and A. magna reside in the small intestine and share similar characteristics in
life cycle to A. perfoliata; however, they are only reported sporadically and are considered
to not be clinically relevant (Nielsen, 2016a; Rehbein et al., 2013). Therefore, they will not
be discussed further. A. perfoliata is considered unique among tapeworms, as it is found at
the ileocecal junction and within the cecum of horses, as most occur within the small
intestine of their definitive host. Horses obtain infection by ingesting oribatid pasture mites
that contain the infective cysticercoid stage and accumulate these parasites throughout the
grazing season (Denegri, 1993); therefore, the highest worm burdens are usually found in
the in second half of the year in the northern hemisphere, after the grazing season (Tomczuk

et al., 2015). Infections with A. perfoliata may lead to hyperemia, mucosal thickening, and
necrotic ulcers (Nilsson et al., 1995; Pearson et al., 1993; Williamson et al., 1997) of the
ileocecal junction and cecum. The inflammatory reactions to this parasite will be reviewed
in 1.3.2.3. Finally, associations between A. perfoliata and ileocecal, cecocolic, and
cecocecal intussusception, rupture, ileal hypertrophy, and ileal impaction are also reported
(Barclay et al., 1982; Beroza et al., 1986; Foerner et al., 1980; Owen et al., 1989; Proudman
et al., 1998; Ryu et al., 2001).
1.1.2 Ascarids
In the phylum Nematoda, within the class Secerentea, there are several orders and
suborders that infect the gastrointestinal tract of horses, including: Ascaridida, Spirurida,
Oxyurida, Rhabditida, and Strongylida. They reside from the stomach, small intestine, and
large intestine of the horse. Within the order Ascaridida, is Parascaris spp., including
Parascaris equorum and Parascaris univalens, with the former being most well-known
but the latter more common worldwide (Martin et al., 2018; Nielsen et al., 2014). Horses
are infected by ingesting the larvated eggs in the environment. The larvae hatch in the small
intestine, and then undergo hepatotracheal migration, where they will mature and molt in
the lungs (Clayton and Duncan, 1979). When they arrive back to the small intestine, the
later stages mature into adults and start reproducing sexually (H. M. Clayton and Duncan,
1979). The entire process takes approximately 12-16 weeks (H. M. Clayton and Duncan,
1979). Parascaris spp. are common parasites in the small intestines of foals, and can cause
severe intestinal impaction and potentially lead to intestinal rupture and death (Cribb et al.,
2006; Southwood et al., 1966; Tatz et al., 2012). Horses gain immunity to the parasite,
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though the exact mechanism is unknown, and will tend to not have significant burdens
above 1-2 years of age (Clayton and Duncan, 1979; Nielsen, 2016b).
1.1.3 Spirurids
Draschia megastoma, Habronema microstoma, and Habronema muscae are within
the spirurids. Horses become infected when flies, primarily Musca autumnalis, Musca
domestica, and Stomoxys calcitrans, carrying the infected larvae land near the lips, open
wounds, or conjunctiva of the horse (Pugh et al., 2014). When placed near the mouth, the
infective larvae are ingested and migrate to the stomach to complete the lifecycle. In the
stomach, the adults pass larvated eggs in the feces, which are ingested by fly larvae
maggots, and then undergo maturation to the infective stage within the fly larvae as they
molt and mature (Pugh et al., 2014). The parasitic adults live in the glandular portion of
the stomach, with D. megastoma inducing large fibrous nodules along the margo plicatus.
However, it is the larvae that cause the most significant disease during aberrant migration
in the cutaneous and conjunctival tissues (Pugh et al., 2014; Rebhun et al., 1981;
Underwood, 1936). This disease, known commonly as summer sores or habronemiasis,
causes severe ulceration and granulation of wounds and the conjunctiva of the horse (Pugh
et al., 2014).
1.1.4 Oxyurids
Horses are also host to the oxyurid parasites Oxyuris equi and Probstmayria
vivipara, both of which live in the large intestine of the horse. Horses become infected with
O. equi by ingesting the larvated egg (Enigk, 1949; Hasslinger, 1990). The larvae hatch
and mature within the cecum (CEC), ventral colon (VC) and dorsal colon (DC) (Enigk,
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1949; Hasslinger, 1990; Wetzel, 1930a). Oxyuris equi gravid females will deposit eggs
around the edge of the anus, leading to intense anal pruritus, tail rubbing, and potential
behavioral issues (Enigk, 1949; Hasslinger, 1990; Reinemeyer and Nielsen, 2014). These
females can be large, up to 15 cm, have a pointed tail, and are routinely observed by horse
owners in the feces (Reinemeyer and Nielsen, 2014). Probstmayria vivipara passes larvae
into the lumen of the large intestine and undergoes auto reinfection within the large
intestine of the host. There are no clinical signs associated with this parasite, and while
most horses likely harbor all life stages, it is missed routinely due to its small size (<3mm
)(Slocombe, 1985; Tolliver et al., 1987).
1.1.5 Rhabditids
Within the order Rhabditida is a very unique group of parasites with unusual
lifecycles. In horses, only Strongyloides westeri is known to infect the gastrointestinal tract.
Adult females live in the small intestine of foals and reproduce parthenogenically. Larvated
eggs are passed in the feces, and hatch and grow to the infective stage, where, they can
either continue to grow and reproduce sexually in the environment or infect the host and
continue the lifecycle. Foals are infected by ingesting mare’s milk, percutaneous
penetration,

or

by

ingestion

from

the

environment.

The parasite has been loosely associated with foal frenzy syndrome and dermatitis, as well
as foal heat diarrhea (Dewes, 1989; Lyons et al., 1973; Netherwood et al., 1996).
1.1.6 Strongylids
Finally, the order Strongylida is the main target of current adult equine parasite
control. Within the Strongylida, one Trichostrongyle, Trichostrongylus axei infects the
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stomach, and is important due to it being potentially zoonotic; however, most human cases
currently seem to originate in the middle east and southeast Asia (Phosuk et al., 2013;
Sharifdini et al., 2017). Of the strongyles, there are two classifications within horses, the
cyathostomins (Cyathostominae; small strongyles), which will be the main focus of this
dissertation, and the large strongyles (Strongylinae). The parasitic adults live in the CEC,
VC, and DC. In domestic horses, the large strongyles consist of 14 species in 5 genera:
Bidentostomum, Craterostomum, Oesophagodontus, Strongylus, and Triodontophorus
(Lichtenfels et al., 2008). Of these, the most discussed due to pathogenicity are the three
Strongylus species. Strongylus vulgaris, S. edentatus, and S. equinus undergo extensive
migration in the horse. The most concerning of the three is S. vulgaris, whose larvae
migrate through the aorta and cranial mesenteric, renal, and celiac arteries (Drudge, 1979;
Slocombe, 1985). This produces significant arteritis, which leads to hemodynamic
turbulence, thrombi formation, non-strangulating infarction, and death (Drudge, 1979;
Duncan and Pirie, 1975; Nielsen et al., 2016). This parasite was the main target of control
starting in the 1950s (Lyons et al., 1999); however, it has become rare in the United States,
due to intense deworming regimens (Herd, 1990).
1.2

Cyathostomins in Equids
Cyathostomins are a unique group of parasites consisting of 14 genera and over 50

species (Lichtenfels et al., 2008). Within the last 30 years, due to the decreased prevalence
of S. vulgaris, cyathostomins have become the main target of most deworming programs
(Herd, 1990). Currently, cyathostomins are the strongyles that are most likely to cause
disease in horses in North America and have widespread resistance to 2 of 3 available drug
classes (Abbott et al., n.d.; Bellaw et al., 2018; Eysker et al., 1989; Gokbulut and McKellar,
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2018; Lester et al., 2013; Monahan et al., 1998; Nielsen et al., 2018a; Peregrine et al., 2014;
Reinemeyer et al., 2015). They are unique among strongylids, due to location within the
host and life cycle.
1.2.1 Life Cycle
The life cycle of cyathostomins has several characteristics of a classic strongylid
lifecycle; however, they undergo unique phases that are clinically important for the disease
process. Adults are found in the lumen of the CEC, VC, and DC. They copulate as a pair
and the female then passes eggs into the organ lumen. The eggs are then shed within the
feces, where they larvate to the first larval stage (L1) within the egg, in as little as 12 hours
(Ogbourne, 1972; Rupashinge and Ogbourne, 1978). The larvae, under favorable
conditions of warm temperature and high humidity, will then hatch. The L1 larvae then
develop and molt to the L2 larvae. Both of these stages are coprophagic and feed to gain
nutrients and energy to grow into the infective L3. The infective L3 larvae have a sheath
(the cuticle from the L2 stage) to protect them from harsh environmental conditions and
can survive for several months on pasture. At this stage, they do not acquire nutrients, and
actively move to locations where horses will ingest them.

6

Figure 1-1. The lifecycle of cyathostominae within the horse. A. Adults in the lumen
of the large intestine mate, and the female deposits eggs into the ingesta. B. Eggs are
passed in the feces. C. Eggs embryonate and larvate to the L1 stage. D. L1 hatches
into the environment. E. L1 molts to the L2 stage. F. L2 molts to the L3 stage, which
infects the horse. G. After the horse ingests the L3, it encysts, to be then known as
the EL3. H. The EL3 devlops and molts to the LL3/L4 stage within the tissue. The
L4 excysts, and enters the lumen of the large intestine, where they molt to the adult
stage (A) and continue the lifecycle. The period of time to go from B-F (egg to
infective L3) is typically 14 days on pasture. To go from F to A, the prepatent
period, is 6 weeks to 2 years (Ogbourne, 1975).
The favorable conditions for environmental cyathostomin stages (eggs and larvae)
have been well studied and modelled. The optimum temperatures for eggs to hatch and
grow to the infective stage has been observed in vitro. The optimum temperature range is
25-33C, with highest infective stage larval yield at 28C (Lucker, 1941; Mfitilodze and
Hutchinson, 1987; Ogbourne, 1972; Rupashinge and Ogbourne, 1978). The lower limit for
egg hatching has been observed to be between 7.5-10C, with the upper limit at 38C; no
eggs have observed to hatch at <4C, and they die quickly at 40C (Lucker, 1941;
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Mfitilodze and Hutchinson, 1987; Ogbourne, 1972; Rupashinge and Ogbourne, 1978).
Studies have also shown that long term freezing reduces larval yield; however,
unembryonated eggs withstand colder temperatures more so than embryonated eggs, and
L1 and L2 larvae were the most susceptible (Lucker, 1941; Rupashinge and Ogbourne,
1978; Zahner et al., 1997). L3 larvae are less susceptible to cold and more susceptible to
higher temperatures. L3s survive longer at -5 and 3C than at 26 and 31C (Lucker, 1941;
Rupashinge and Ogbourne, 1978; Zahner et al., 1997). The most detrimental effect on
growth and survival was not a single freeze, but repeated freeze/thaw cycles or long term
freezing over several months (Lucker, 1941; Rupashinge and Ogbourne, 1978; Zahner et
al., 1997).
Once ingested by the horse, the L3 larvae exsheath in the small intestine, and then
continue their migration to the large intestine. The L3 larvae are then considered an early
third stage larva (EL3), which penetrates the mucosa of the CEC, VC, and DC, where a
cyst is formed from connective tissue around the larvae (Ogbourne, 1978). At this point,
the larvae may undergo arrested development (hypobiosis), where they remain dormant
from 2 weeks to 2 years or more. (Gibson, 1953; Ogbourne, 1975). At this stage, it is
suggested that no growth and activity occurs. Hypobiosis has been related to environmental
factors, such as larval uptake, host factors, such as their individual immune response and
age, and even due to the presence of other parasites (Smith, 1976a, 1976b). It has been
suggested that the luminal stages have a negative feedback that inhibits the larval stages
from further development. Removal of the adult parasites then stimulates the development
of the inhibited larvae (Smith, 1976a, 1976b). Trickle experimental infections carried out
to mimic how a host would obtain the parasites, have been shown to induce greater arrested
8

development than large quantities of infective larvae administered at once, indicating a
feedback mechanism between the larvae, host, and luminal stages (Love et al., 1999). Once
the larvae resume development, they molt into the 4th larval stage, and then excyst into the
lumen of the intestine. In the intestine, they will undergo one final molt to the adult stage
(Ogbourne, 1978). Overall, the prepatent period, the time from ingestion to eggs being
passed in the feces can occur in as little as 2-3 months, but can be as long as two to three
years (Gibson, 1953; Ogbourne, 1975; Round, 1969; Smith, 1976a).

1.2.2 Cyathostomins and their nutrient requirement and acquirement
When discussing cyathostomins and all parasitic stages, little work has investigated
the nutrient needs and uptake of the parasites. This is due to the difficulty of evaluating the
parasitic stages, particularly in vitro (0). However, studies have been performed with the
environmental stages of these parasites.
Environmental stages are thought to be bacteriophagic and coprophagic, due to
larval growth habits, composition of the larvae’s intestinal cells, and inference from other
strongylid parasites with similar life cycles. It is also noted that the lipids in the intestinal
cells of L3 larvae are used to assess viability and survivability, with lower concentrations
indicating lower infectivity rates (Baker et al., 1939). Studies have noted that repeated
exposure to differing environmental conditions and long-term storage severely impact
survival and lipid concentrations as well (Baker et al., 1939; Giovannola, 1936; Medica
and Sukhdeo, 1997).
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We do not know what or if the mucosal larval stage feeds on, whether it be the host
or host secretions, passively absorbing nutrients from the intestinal content, or not feeding
at all. Some theorize that no additional nutrients are required while in the larval stage, while
others hypothesize that they feed on blood, due to bright red color of some of the larvae
and their prominent tooth within the buccal capsule, or that they acquire nutrients from
local cells and secretions (Cuillé et al., 1913; Ogbourne, 1978). It is important to note that
there are those larvae that are undergoing hypobiosis, which would lead to reduced nutrient
requirements, whereas developing larvae which likely do have differing metabolic
requirements. Due to the difficulty of maintaining these larva stages in vitro (0), much is
not known and subject to speculation and hypotheses.
There are two schools of thought on the feeding behavior of adult cyathostomins.
One group theorizes that adults feed on the host and ingest blood and other serous nutrients
by attaching to the large intestinal wall (Le Roux, 1924; Wetzel, 1930b). The more popular
opinion is that the adults are bacteriophagic/coprophagic and survive off of luminal
contents (Ihle, 1922; Looss, 1901; Rai, 1961; Theiler, 1923). This is due to the location of
the adults found at necropsy, where they have been described as attached to the mucosa,
along the mucosa, or within the luminal contents from just after death to a few hours,
depending on the timing of necropsy (Ihle, 1922; Le Roux, 1924; Rai, 1961; Wetzel,
1930b). It is important to note that our lab has not seen cyathostomin adults attached to the
mucosa (personal experience). Again, due to the difficulty of maintaining the adults in vitro
(0), little is known about their nutrient requirements.
The species distribution of encysted cyathostomins within the mucosa of the large
intestine remains largely unknown due to a lack of methods for differentiation of these
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larval stages. One work (Ogbourne, 1975) suggests that of the 50 species described in
equids, only 4 can be morphologically identified at the fourth larval stage. The species
reported to infect the domestic horse in North America are reported in Table 1-1. Different
species prefer different organs (Bellaw et al., 2018; Matheison, 1964; Ogbourne, 1978,
1975; Reinemeyer et al., 1986); however, the species prevalence and relative abundance
may be impacted by treatments (Bellaw et al., 2018).
Table 1-1. Species of small strongyles that infect the domestic horse. Asterisks
indicate that it can be found infecting horses in North America. Information taken
from Lichtenfels, 2008.
Cyathostomum

Coronocyclus

Cylicostephanus

Skrjabinodentus

Cylicodontophorus

Cylicocyclus

C. tetracanthum*

C. coronatus*

C. calicatus*

S. tshoijoi

C. bicoronatus*

C. radiatus*

C. alveatum*

C. labiatus*

C. asymetricus*

T. gobi

C. ashworthi*

C. catinatum*

C. labratus*

C. bidentatus*

C. auriculatus*
C.

C. montgomeryi

C. sagittatus

C. goldi*

brevicapsulatus
*

C. pateratum*

C. ulambajari

C. hybridus*

C. elongatus*

C.
C. insigne*
longibursatus*
C.
C. minutus*
leptostomum*
C. nassatus*
C. ultrajectinus*
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Poteriostomum

Parapoteriostomum

Hsiungia

Caballonema

Gyalocephalus

Petrovinema

P. mettami*

H. pekingensis

C. longicapsulatum

G. capitatus*

P. skrjabini

P.
imparidentatum*
P.
P. ratzii*

P. euproctus*
poculatum*
P. mongolica

Table 1-2. (continued)
1.2.3 Pathogenicity and pathophysiology
While early reports associated cyathostomins with disease, they were generally
considered of little clinical importance, especially when compared to other parasites, like
S. vulgaris (Cuillé et al., 1913). After the significant reduction S. vulgaris in managed
herds, attention was drawn to horses presented for a severe clinical disease that was linked
to larval cyathostomins, and therefore the disease was named “larval cyathostominosis”
(Herd, 1990; Love et al., 1999). This disease occurs when there is mass excystment of L4
larvae from the mucosa into the lumen of the large intestine (Davidson et al., 2002; Love
et al., 1999; Murphy and Love, 1997; Ogbourne, 1978).
The primary clinical signs associated with larval cyathostominosis are profuse
watery diarrhea, weight loss, and emaciation (Love et al., 1999). Disease is characterized
by a severe, sudden onset diarrhea, which then leads to dehydration, emaciation, and
resulting in potential death in two to three weeks after clinical signs became apparent (Love
et al., 1999; Peregrine et al., 2006). The diarrhea and emaciation are generally accompanied
by a protein-losing enteropathy, hypoproteinemia, and edema (Love et al., 1999).
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In Europe, a distinct seasonality and age distribution have been previously noted
amongst larval cyathostominosis cases. Most cases are observed in late winter and early
spring in horses 2-5 years of age (Reid et al., 1995). Whereas, in North America, cases
occurred through October to May, with the majority occurring in October through
December in horses with a median age of 1 year (Peregrine et al., 2006). Cyathostomins
have also been implicated in disease in horses with recurrent diarrhea and weight loss,
edema, and pyrexia without diarrhea in the fall (Mair, 1994) and other studies have
implicated cyathostomins in horses with weight loss of several months duration prior to
the onset of diarrhea (Mirck, 1977; Murphy et al., 1997; Reilly et al., 1993). Experimental
infections with cyathostomin larvae have exhibited minor effects from change in fecal
consistency and decreased intestinal motility to reduced weight gain and diarrhea for up
to 52 weeks post infection (Love et al., 1999; Murphy and Love, 1997; Scháňková et al.,
2014).
As far as diagnosis of clinical disease, there are no pathognomonic findings.
Complete blood counts (CBC) and chemistry may reveal a neutrophilia and
hypoalbuminemia, which fit with clinical signs mentioned above (Mair, 1994; Murphy et
al., 1997). Other findings, that have been associated, are anemia, eosinophilia, and an
increase in serum alkaline phosphatase (Murphy et al., 1997).
Cyathostomins have been implicated in several different types of colic, including:
cecocecal intussusception, non-strangulating infarctions, and nonspecific medical colic
(Lyons et al., 1994; Mair et al., 1999; Mair and Pearson, 1995; Uhlinger, 1990). This loose
association with colic is reported for many diseases and is considered nonspecific in many
cases, as colic arises from a broad range of etiologies. One possible mechanism behind
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colic is decreased intestinal motility. This has been shown to occur in mixed cyathostomin
infections; however, the exact mechanisms have not been identified at this time (Bueno et
al., 1979).
At the mucosal level, tissues from horses with clinical disease and clinically healthy
horses with cyathostomin infections are well described. In horses diagnosed with acute
larval cyathostominosis, generalized inflammation and edema of the CEC and VC and DC
occurs, with fibrin deposits, hemorrhagic foci and necrotic and granulomatous nodules
throughout the mucosa. Large numbers of larvae are found both within the mucosa (2050/cm2) and the contents, and there is enlargement of the mesenteric lymph nodes
(Matheison, 1964; Tiunov, 1953; Velichkin, 1952). Histopathological examinations have
revealed diffuse edema and disruption of the intestinal mucosa with a diffuse marked
cellular response in the lamina propria and/or submucosa (Matheison, 1964; Tiunov, 1953;
Velichkin, 1952). In a few studies, this reaction was more evident around encapsulated
larvae (Giles et al., 1985; Matheison, 1964; Tiunov, 1953). The cellular response includes
mixed populations of mononuclear cells, as mentioned above, eosinophils, and
macrophages. Fibrous capsules were also found surrounding the larvae, as well as areas of
hemorrhage with eosinophils. Dilated submucosal lymphatics and epithelial shedding were
also noted. In one study, the inflammation in the large intestine was accompanied by
inflammation and infiltration of inflammatory cells and edema into the lamina propria and
submucosa of the jejunum and rectum (Church et al., 1986). Caution should be used when
analyzing these findings, as these are locations that the larvae do not normally infect.
Clinically normal horses also exhibit pathology to the invasion of the parasites.
Surrounding the larvae are fibroblasts that create a thickened layer of connective tissue,
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encapsulating the larvae. Lymphocytes, plasma cells, macrophages, mast cells, neutrophils,
and eosinophils surround the encapsulated larvae and occur infiltrate between the larvae
and the basement membrane of the mucosa (Matheison, 1964; Steinbach et al., 2006;
Tiunov, 1953). As the larvae grow, they increase in size, distort the normal tissue
architecture, and induce goblet cell hyperplasia (GCH) and hypertrophy (Matheison,
1964). Larvae that encyst in the lamina propria have been reported to induce a primarily
lymphocytic, plasmocytic reaction with a small fibrous capsule whereas larvae in the
submucosa produce large fibrous and collagenous capsules with a plasmocytic,
eosinophilic, histiocytic invasion (Matheison, 1964; Nielsen et al., 2015; Steinbach et al.,
2006; Tiunov, 1953).
The current belief is that the disease causes a protein-losing enteropathy due to the
mass excystment compromising the mucosal barrier and integrity (Love et al., 1999). Love
et al. evaluated urinary excretion of chromium ethylenediaminetetraacetate to assess
intestinal permeability. They found that the mucosal barrier was compromised following
cyathostomin infections (Love et al., 1991). However, to assess a true protein- losing
enteropathy, plasma proteins must be identified within the contents of the large intestine
(Love et al., 1991). Studies have evaluated protein loss in later stage cyathostomin
infections using radioisotope labeled protein markers; however, no differences were shown
between infected ponies and controls (Love et al., 1991).
1.2.4 Treatment
Treatment options have been developed over the years to target several different
species of parasites, and these are now known as “broad spectrum” anthelmintics. Over the
past 100 years, 25 compounds in 6 drug classes were marketed (Lyons et al., 1999);
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however, three drug classes with six compounds are currently available and labeled for use
against cyathostomins in the United States: The benzimidazoles, pyrantel salts, and
macrocyclic lactones (Branan et al., 2018; Nielsen et al., 2019). Each of these has a
different mechanism of action, and differing levels of resistance reported in cyathostomins.
They also target different stages of the parasite. There is also reports on how anthelmintics
interact with the parasites and the host immune system. It has been documented that some
adulticidal therapies (those strictly targeting adult & luminal cyathostomins) may increase
the risk of larval cyathostominosis (Reid et al., 1995). Veterinarians and horse owners have
raised concern that larvicidal activity may also increase the inflammatory reaction from
dying larvae; however, this has not been evaluated in any studies. The following section
will introduce the anthelmintic drug classes currently available in the United States. The
inflammatory reactions that have been studied will be discussed in 1.3.2.1.1. Anthelmintic
resistance will be mentioned; however, this is not a primary focus of this dissertation, aside
from what effect a given anthelmintic may have on worm burdens and the immune
response.
1.2.4.1 Benzimidazoles
Benzimidazoles (BZs) are well known parasiticides in the equine market and have
been commercially available since the 1960s, making them the oldest drug class currently
available in horses (Lyons et al., 1999; Nielsen et al., 2019). Benzimidazoles are labeled
as broad spectrum anthelmintics, targeting large and small strongyles, ascarids, pinworms,
and intestinal threadworms. Benzimidazoles inhibit the beta-tubulin formation within the
nematodes. This leads to paralysis of the intestinal tract of the worms, leading to starvation
and death, or a “slow-kill” (Lacey, 1988) These drugs have a wide margin of safety in
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animals, as they are preferential to helminth and not mammalian microtubules (Lacey,
1988). The current compounds available in the US are fenbendazole and oxibendazole.
Fenbendazole is sold in two dosing regimens: a single oral dose at 5 mg/kg and a five-day
double dose at 10mg/kg. The main difference between these two treatment regimens is the
ability of the five-day double dose to target the migrating and arrested larvae of the large
strongyles, ascarids, and cyathostomins12. Anthelmintic resistance is reported to be
widespread in cyathostomins to both the single and five-day double dose of fenbendazole
and across all stages (Bellaw et al., 2018; Branan et al., 2018; Lyons et al., 2016;
Reinemeyer et al., 2015).
1.2.4.2 Pyrantel Salts
Pyrantel salts, also known as pyrimidine compounds, are the second oldest drug
class used in horses in the United States today. These were originally made available in the
1970s (Lyons et al., 1999). Pyrantel exists in two formulations for horses: Pyrantel pamoate
and pyrantel tartrate. Pyrantel pamoate is a single oral dose suspension or paste, whereas
pyrantel tartrate is a continuous daily pelleted feed. Pyrantel pamoate, at 6.6 mg/kg, is
labeled as a broad spectrum product; however, it does not have larvicidal efficacy against
encysted mucosal or migrating larvae3. Pyrantel tartrate, at 2.65 mg/kg daily has similar
label claims as pyrantel pamoate; however, the label claim states that it is intended for the
use of prevention of S. vulgaris larval infections4.

1 https://www.merck-animal-health-usa.com/species/equine/product/PANACUR_POWERPAC
2 https://www.merck-animal-health-usa.com/species/equine/product/PANACUR_PASTE_25_GRAM
3 https://www.zoetisus.com/products/horses/strongid-t.aspx
4 https://www.zoetisus.com/products/horses/strongid-c-c-2x.aspx
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Pyrantel works by both depolarizing and causing excitatory effects on the muscle
fibers of helminths (Reinemeyer, 2016). It is a nicotinic acetylcholine receptor agonist and
acts on ionotropic receptors and not muscarinic receptors (Reinemeyer, 2016). It has a high
affinity for nematode receptors, specifically. Resistance to these compounds is common in
cyathostomins throughout the US (Branan et al., 2018; Reinemeyer, 2016).
1.2.4.3 Macrocyclic Lactones
Macrocyclic Lactones (MLs) were introduced in the 1980s as broad spectrum
anthelmintics (Lyons et al., 1999). The first compound introduced was ivermectin, an
avermectin class drug of MLs. Ivermectin induces flaccid paralysis and starvation by
binding to the parasite’s glutamate gated chloride channels in the muscle and neural tissue,
most specifically the somatic and pharyngeal muscles (Martin et al., 2016). Moxidectin
was introduced in the 1990s and is a milbemycin ML. It too causes flaccid paralysis and
starvation by the same mechanism as ivermectin (Martin et al., 2016). There are few key
differences between ivermectin and moxidectin. Moxidectin is more lipophilic, which
allows it to persist longer in the tissues and also allows it better access to the encysted
stages of cyathostomins. Ivermectin, at 0.2 mg/kg single oral dose, is not labeled to target
the encysted stages5; and the efficacies vary and are reported in Table 1-3; however, the
single study reporting the high encysted larval efficacy is an apparent outlier. Moxidectin,
on the other hand, at 0.4 mg/kg single oral dose, is labeled against the LL3 and L4s, EL3s
in the US6. Moxidectin range of efficacies against the stages are reported in Table 1-3. One
final note is that praziquantel, one of two compounds effective against equine tapeworms,
5 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c8bf574-0b67-4248-a8f6-130e8c5c1cd3
6 https://www.zoetisus.com/contact/pages/product_information/msds_pi/pi/Quest_Gel.pdf
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the other being pyrantel; pamoate, is only available in combination with ivermectin or
moxidectin.
Table 1-3. Previously reported percent efficacies of moxidectin and ivermectin in
horses with natural and expiremental cyathostomin infections. Asterisk indicates
that the percentages were calculated based off of data presented, and not calculated
by the authors. Dash indicates data not provided and blanks indicate that the
anthelmintic was not evaluated in the study,
Moxidectin
Ivermectin
Study

EL3

LL3/L4s

Total

(Klei et al.,
1993)
(Xiao et al.,
1994)

0

62.679.1

-

(Love,
1995)
(Monahan et
al., 1996)*

34.0-52.6

16.750.0

37.887

(Eysker et
al., 1997)

18.5

89.6

17.2

(Steinbach
et al.,
2006)*

96.7

100

100

(Reinemeyer
et al., 2015)

63.6

85.2

-

(Bellaw et
al., 2018)

71.8-73.8

0.9- 74.6

-

EL3

LL3/L4s

Total

52.8

75.8

34.6

10.1%

0

-

-

77%

-

0

0

0

1.2.5 Diagnosis
Diagnosing cyathostomin infection versus disease has led to much confusion and
frustration for veterinary practitioners, horse owners, and even parasitologists. Disease is
a clinical diagnosis, based on clinical signs, CBC/Chemistry and ultrasound, response to
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treatment, and necropsy findings (Love et al., 1999; Peregrine et al., 2006). Routine
diagnostic testing for cyathostomins are as follows; however, they test for infection and
not disease.
1.2.5.1 Coprological Methods
The most common diagnostic tests involve using feces to identify infections. This
was first used in the early 1900s, after the discovery that many parasites pass stages in the
feces (Bass, 1909). This section will cover the most common fecal diagnostics for
cyathostomins below.
1.2.5.1.1 FECAL FLOTATION AND EGG COUNTS
The primary fecal diagnostic method is using a fecal flotation. Parasite ova, larvae,
or cysts are floated based on a solution with greater specific gravity than the parasite
objects, but lower than miscellaneous fecal particulates. The primary principal is to
increase parasite yield and decrease background particulates. There are a few different
flotation methods, including passive, active, qualitative and quantitative.
Passive flotation involves allowing eggs to rise in the flotation media using just
gravity to separate the parasitic stages and feces. Active flotation involves enhanced G
force, usually with a centrifuge, to force the parasitic stages to the surface and particulates
to the bottom (Dryden et al., 2005).
Qualitative flotations are generally used in small animal practice. This involves
feces, usually a thumb sized amount, that is not accurately measured by neither weight nor
volume. The number of parasite ova, larvae, or oocysts, is generally not considered
important in small animal practice, as worm burden does not correlate with disease and
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spread (Dryden et al., 2005). In large animals, quantitative fecal techniques, also known as
fecal egg counts (FECs), are applied more commonly. With FECs, such as determined with
McMaster or Mini-FLOTAC techniques, a known quantity of feces is used and added to a
known quantity of flotation medium, and a subsample examined underneath the
microscope (Ballweber et al., 2014; Cringoli et al., 2017a). This gives an estimation of the
number of eggs per gram (EPG) being passed in the feces. EPG does not correlate with
worm burden and disease. FECs are used for herd management and managing infection
pressure and resistance (Nielsen et al., 2019). With regards to strongyles in horses, the eggs
passed in the feces cannot be differentiated between genera or species by morphologic
appearance, and therefore cannot be used to differentiate types of strongyle infections.
1.2.5.1.2 COPROCULTURE
Coprocultures are the next step for differentiating strongyle infections in horses.
The principal is simple: allow the eggs to hatch and larvate to the infective stage, as they
would on pasture. At this stage, the Strongylus spp., Triodontophorus spp., and a few of
the strongylid and cyathostomin genera, and a few species, can be differentiated based on
size and number of intestinal cells (Russell, 1948). This is useful in identifying large
strongyle infections within a herd to develop management protocols (Bellaw and Nielsen,
2015; Kuzmina et al., 2012).
1.2.5.2 Enzyme-Linked Immunosorbent Assays (ELISA)
Enzyme-Linked Immunosorbent Assays (ELISAs) were first described in the 1970s
(Engvall, 1971). The testing usually involves detecting and potentially quantifying antigen
and antibodies (along with other peptides, proteins, and potentially hormones) (Engvall,
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2010). While this method is common in other host species for diagnosing parasite infection
(i.e., heartworm in dogs (Zecca et al., 2018)), it is not routinely performed in horses in the
US. In Europe and a few diagnostic laboratories in the US, an A. perfoliata antibody
ELISA, which uses saliva and/or serum, is used to identify exposure and infection (Nielsen,
2016a). For small strongyles, a commercial test became available in the United Kingdom
in 20197. While a previous serum antibody ELISA screened for infection of all parasitic
stages for 11 species of cyathostomins (Mitchell et al., 2016), this platform is similar to
Tzelos et al., and uses 5 cyathostomin antigens for the 5 most commons species in horses
(Tzelos et al., 2020). The current sensitivity is 98% and specificity is 81%; however, it
does not differentiate between the luminal and encysted stages8.
1.2.5.3 Polymerase Chain Reaction (PCR)
PCR is a diagnostic and research technique, where the general principle is that PCR
takes small DNA segments and amplifies the target of interest (Mullis et al., 1992). They
can be used for quantification (how much of a target is present) or qualitative testing (is
the target present or not). In veterinary helminth parasitology, PCR has found limited use
in commercialized diagnostic testing; however, various assays have been produced for use
in research (Bredtmann et al., 2017; Davidson et al., 2005a; Hodgkinson et al., 2005;
Manyazewal et al., 2018). In horses, few PCRs are available for diagnosing parasitic
diseases, especially those of helminths (Andersen et al., 2013a). Currently, only one PCR
is available in the United States for detection of Strongylus vulgaris in feces (Andersen et

7 https://www.austindavis.co.uk/small-redworm-blood-test
8 https://cdn.websiteeditor.net/88f85cd9154141f880badb10905b7906/files/uploaded/Austin%2520Davis%2520Small%2520Redworm%2520Guidelines%
2520Final.pdf
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al., 2013b). Others have tested PCR for cyathostomin infections and potential species
differentiation; however, it is not commercially available due to the wide variation of
species of cyathostomins (Bredtmann et al., 2017; Hodgkinson et al., 2005).
A combination PCR-ELISA has been developed for detection of strongyle eggs
(Hodgkinson et al., 2005, 2003). A PCR–ELISA uses portions of PCR products and
amplification to identify and quantify a target. In cyathostomins, this technique has been
developed for the identification of cyathostomin fourth-stage larvae in horses with clinical
cyathostominosis. This PCR-ELISA tested for 6 species and an overall marker for all
cyathostomins. They found that disease was likely due to mixed infections in many cases
(Hodgkinson et al., 2003). Hodgkinson et al. then expanded their PCR-ELISA for testing
the species composition of strongyle eggs after treatment for 19 cyathostomin species to
see their fluctuations after treatment; however, it does not quantify their burden
(Hodgkinson et al., 2005).
Another PCR hybridization is the use of reverse line blot for identification of
strongyle species (Cwiklinski et al., 2012; Ionita et al., 2010; Traversa et al., 2008; Van
Doorn et al., 2010). This, similar to PCR-ELISA, allows for the detection of multiple
species in one sample. It allows visualization of DNA bands on a gel via electrophoresis
of the PCR products (Ionita et al., 2010; Traversa et al., 2008; Van Doorn et al., 2010).
1.2.5.4 In vitro cultivation of cyathostomins
Many studies have used culturing of cyathostomin larvae to the infective L3 stage
for a variety of purposes, including antigen harvesting and anthelmintic testing (Hu et al.,
2018; Kinsella et al., 2002; Payne et al., 2013; Peachey et al., 2016; Van Doorn et al.,
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2010). While these studies are useful for studying cyathostomins, the L3s are not the
parasitic stages in horses, and few comparisons have been made between these and the
parasitic stages, in terms of their in vitro behavior and antigenic responses. Few studies
have attempted to culture the parasitic stages of cyathostomins with little success, as they
do not survive well outside of the host (Brianti et al., 2009; Chapman et al., 1994).
Additionally, adults do not survive well in RPMI 1640 medium for more than 24 hours
(personal communications with Jennifer Bellaw and own observations). This is likely due
to damage during harvesting, lack of proper nutrients, and temperature variability. The use
of rodent models has been previously explored; however, they did not result in patent
infections in rodents (De Blieck and Baudet, 1926; Klei and Chapman, 1999; Schoene,
1938; Scmid and Johannsen, 1937).
1.3

Equine Immune System
1.3.1 Overview of the Equine Immune System
The immune system is a complex barrier of cells, proteins, and signals that protects

the body from foreign invaders. The body does this by responding in different mechanisms
to pathogens (for example), such as bacteria, viruses, fungi, and parasites, generating
inflammation. Through this process, the body must register “self” versus “non-self.” There
are several ways to define the immune system and its response: innate and adapted, type 1
and type 2, proinflammatory and anti-inflammatory, etc.
Several organs and barriers are key to the immune response and protection of the
host. Many of the circulating inflammatory cells are produced centrally, in the bone
marrow or thymus, and occasionally lymph nodes and the spleen, and then migrate
peripherally to lymph nodes, spleen, and mucosal associated tissues (mucosal associated
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lymphoid tissues (MALT): this includes bronchus associated lymphoid tissue (BALT) and
gut-associated lymphoid tissue (GALT)) to finish development and undergo activation.
Cells will also circulate and migrate to the local tissues to react quickly to potential antigen.
Epithelial cells of the skin and mucosa are also a barrier, both physically with clearance
mechanisms and through secretions. These cells can also secrete inflammatory modulators
in response to pathogens, recruiting inflammatory cells to respond (Felippe and Julia.,
2016).This section will be broken down into innate vs adapted, cell types, type 1 and type
2, as well as an overview of cytokines and their potential role in horses.
1.3.1.1 Innate Immune Response
The innate immune system is considered a generalized, unspecific first response to
pathogens (Sun et al., 2014). It involves unspecific cell-mediated immunity and barriers,
including mucosal and skin barriers. All mucosal surfaces, and certain white blood cells,
fall into the innate immune response including neutrophils, eosinophils, macrophages,
dendritic cells, basophils, and mast cells (Sun et al., 2014). Certain cells induce
inflammation and therefore recruitment of other inflammatory cells and upset the desirable
conditions that the pathogen needs for survival (Sun et al., 2014).
1.3.1.2 Adaptive Immune Response
The adaptive immune response involves prior exposure to pathogens, to allow the
immune system to recognize the pathogen from memory (Fagarasan et al., 2010). It allows
for long term recognition of specific pathogens for quick attack. The innate immune
response is still required for the adaptive immune response to mount an attack (Fagarasan
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et al., 2010. The Adaptive immune response is further divided into cell-mediated and
humoral responses (Fagarasan et al., 2010).
1.3.1.3 Type 1 Response
The immune response can further be classified into type 1 and type 2 responses.
Type 1 immune response is typically thought of as acting against intracellular pathogens,
such as bacteria, viruses, and protozoal infections. It’s comprised of both innate and
adaptive immune responses, including interferon-gamma producing cells (such as CD4+ T
helper cells), and cytotoxic lymphocytes (such as CD8+ T cells and natural killer cells).
Cytokine producing cells produce inflammatory markers that can recruit and cause
adaptation of B lymphocytes and other antibodies (Spellberg and Edwards, 2001). Type 1
responses typically allow chronic infection and fibrosis in helminth rodent models
(Spellberg and Edwards, 2001).
1.3.1.4 Type 2 Response
The type 2 immune response is an important component in helminth infections. It
is composed of portions of both the innate and adaptive responses. Type 2 immunity
produces greater quantities of antibody than type one, and also suppresses phagocytosis,
compared to a type one mediated response (Spellberg and Edwards, 2001). Except in the
event of large pathogens, like parasites, type 2 immunity is typically involved with
resolving cell-mediated inflammation (Spellberg and Edwards, 2001). Type 2 immunity
usually causes a diminished worm burden in helminth infection models (Spellberg and
Edwards, 2001).
1.3.1.5 Cells involved in the immune response
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White blood cells are key components of the host pathogen response (Spellberg
and Edwards, 2001). Entire textbooks and theses are dedicated to individual cell types and
arms of their development. This section will give an overview of these cell types and
function, with particular regard to parasitic disease, as these are used to evaluate the
inflammatory response in subsequent chapters.
1.3.1.5.1 NEUTROPHILS
Neutrophils are granulocytes that are a key component of the innate immune
system. Cytokines, such as Interferon-γ (IFN- γ), direct neutrophils to the site of
inflammation, which are released by epithelial cells, mast cells, and macrophages
(Hellebrekers et al., 2018). Neutrophils primarily undergo phagocytosis and degranulation
in response to bacteria and other, primarily intracellular, pathogens (Hellebrekers et al.,
2018). In phagocytosis, they ingest microorganisms to remove them from the surrounding
tissue, destroying the microorganisms in the process (Hellebrekers et al., 2018). During
degranulation, the neutrophils release granules into the surrounding tissue that target the
microorganisms, thereby leading to their death

(Hellebrekers et al., 2018). Finally,

neutrophils may also form neutrophil extracellular traps (NETs) (Caro et al., 2014). These
traps form web fibers between the neutrophils, trapping extracellular bacteria and other
pathogens (Caro et al., 2014). NETs may also serve as a physical barrier to prevent the
infectious agent’s spread (Caro et al., 2014). In cyathostomin infections in horses,
neutrophils are reported to surround the encysted larvae in the tissues (Matheison, 1964;
M. K. Nielsen et al., 2015; Ogbourne, 1978; Steinbach et al., 2006; Tiunov, 1953). In larval
cyathostominosis cases, neutrophilia is a potential component of the disease (Giles et al.,
1985; Mair, 1994; Murphy and Love, 1997); however, neutrophil response, since it is part
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of the innate immunity, is a part of all inflammatory responses and not just parasite
infections.
1.3.1.5.2 EOSINOPHILS
Eosinophils are another key granulocyte of the innate immune system. These cells
are implicated in both parasitic diseases and allergic reactions, and conditions such as
asthma and anaphylaxis (Gleich, 2013). Eosinophils contain a number of important
granules that target helminths during infections and eosinophil proliferation is mediated by
IL-5, and can produce cytokines, such as Interferon- γ, Interleukins 4-6, and 10 (Adamko
et al., 2013; Alam et al., 2013; Cadman et al., 2014; Wennerås et al., 2013).
While eosinophils appear to be a critical component of nematode infections, their
role in worm expulsion has not been identified (Abraham et al., 2013; Allen and
Sutherland, 2014; Klion and Nutman, 2004). In Nippostrongylus brasiliensis infections in
mice, it has been found that a lack of eosinophils increases the susceptibility to infection,
where greater numbers of larvae migrated to the lung, but did not contribute to their
expulsion from the small intestine (Knott et al., 2007). In cyathostomin infections,
eosinophils are reported in response to the larvae (Church et al., 1986; Giles et al., 1985;
Matheison, 1964; Steinbach et al., 2006; Tiunov, 1953); however, eosinophilia is a less
consistent finding in diseased animals (Murphy et al., 1997).
1.3.1.5.3 MACROPHAGES
Macrophages are another key component of the innate immune response. These
phagocytic cells are found throughout the body and the tissues (Rückerl et al., 2013). They
specialize in removing cellular debris, and dead or dying cells, especially in chronic
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inflammation, due to the death and clearance of neutrophils, and also eradicate microbes
(Rückerl et al., 2013). After ingestion of cells, cellular debris, and portion of microbes, the
macrophage can present antigens to helper T cells, initiating the adaptive immune response
in hosts (Rückerl et al., 2013). Alternatively activated macrophages promote wound and
tissue healing after infections and are key components of the Th2 and anti-inflammatory
response (Rückerl et al., 2013).
1.3.1.5.4 DENDRITIC CELLS
Dendritic cells are antigen presenting cells that are specialized for the initiation of
the adaptive immune response (Schraml and Reis e Sousa, 2015). Dendritic cells present
antigen to T lymphocytes, forming a link between the innate and adaptive immune response
by initiating and inducing T cell responses (Schraml and Reis e Sousa, 2015). They
upregulate the expression of major histocompatibility complexes (MHCs) and secrete
cytokines, such as Interleukin-12 to activate naïve T lymphocytes (Schraml and Reis e
Sousa, 2015).
When dendritic cells are absent in several parasite models, a delayed and or
compromised Th2 cell response occurs, indicating their crucial role in adaptive immunity
(Ohnmacht et al., 2009; Reynolds et al., 2012)
1.3.1.5.5 BASOPHILS
Basophils are the least numerous granulocytes within the equine immune system,
but they are the largest, accounting for <1% of peripheral white blood cells (Karasuyama
et al., 2011). They contribute to acute and chronic allergic reactions and parasitic
infections, especially in ectoparasitic infestations or parasites that ingest blood, as they
29

secret heparin, and anticlotting factor in the blood (Karasuyama et al., 2011). Basophils are
also able to regulate T cells and their mechanisms and responses, and bind to
immunoglobulin E, which is implicated in parasitic infections (Karasuyama et al., 2011).
In some parasitic infections, basophils appear to be necessary for optimal worm expulsion
(Reynolds et al., 2012).
1.3.1.5.6 MAST CELLS
Mast cells are another granulocyte, similar to basophils, that contain histamine and
heparin (Mukai et al., 2018). They are also important in allergic and parasitic reactions,
host defense, and immune tolerance (Mukai et al., 2018). When activated, mast cells
release granules in response to immunoglobulin E or other pathogen recognition
pathways(Mukai et al., 2018). When the mast cell degranulates, it releases important
mediators, such as tumor necrosis factor- ⍺, interleukin-4, and certain chemokines, such as
eosinophil chemotactic factor, to attract other cell types (Mukai et al., 2018).
In Heligosomoides polygyrus infections in rodents, activated macrophages are an
essential component in the hosts response to worm infection and expulsion. They also
promote repairment of tissue damage created from the migration of H. polygyrus through
the tissues (Reynolds et al., 2012).
1.3.1.5.7 B LYMPHOCYTES
B lymphocytes, or B cells, are a key component of humoral immunity of the
adaptive immune system (Harris and Gause, 2011; Ludwig-Portugall and Layland, 2012).
Their name arises because they initially develop in the bone marrow (Harris and Gause,
2011; Ludwig-Portugall and Layland, 2012). B cells secrete antibodies that bind to antigens
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to target them for clearance and removal (Harris and Gause, 2011; Ludwig-Portugall and
Layland, 2012). Depending on the type, they can also secrete cytokines and present
antigens to other cell types (Harris and Gause, 2011; Ludwig-Portugall and Layland, 2012).
On the cell surface, they express clusters of differentiation (CDs), during different phases
of their life cycle (Casan et al., 2018). These can be used to identify them in the tissues.
For example, we used a common marker, CD20 to identify B cells within the tissues of
horses infected with cyathostomins (Steuer et al, 2018). CD20 concentrations increase until
maturity (Casan et al., 2018). It’s exact function is not known, but it is critical for the
immune response and suspected that it acts as a calcium channel in the membrane (Harris
and Gause, 2011; Ludwig-Portugall and Layland, 2012). There are several types of B cells,
including memory cells and plasma cells. Memory cells are designed to generate a rapid
response to a pathogen that their activated parent B cell previously encountered (Harris and
Gause, 2011; Ludwig-Portugall and Layland, 2012). Plasma cells are long-lived cells that
secrete antibodies and immunoglobulins to mediate both B and T cells (Harris and Gause,
2011; Ludwig-Portugall and Layland, 2012).
1.3.1.5.8 T LYMPHOCYTES
T lymphocytes are a key factor of the cell-mediated adaptive immune response.
They are so aptly named due to maturation and differentiation in the thymus of the host
(Taylor et al., 2012). There are several types of T cells, including T helper cells, cytotoxic
T cells, memory T cells, regulatory T cells, and innate T cells, such as Natural Killer T
(NKT) cells and mucosal associated invariant T (MAIT) cells. T helper cells express CD4+
on their surface. They are activated when presented an antigen, and then secrete certain
cytokines, depending on the type of helper cells. There are Th1, Th2, Th17, Th9, and Tfh
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type helper cells within the body, named based on when they were identified and what they
may excrete (Taylor et al., 2012). For example, Th1 cells are key in the inflammatory
response in regard to intracellular microbes. They, in general, excrete cytokines such as
Interferon- γ (Taylor et al., 2012). Th2 cells aid the B cells in production of antibodies and
their differentiation. They secrete cytokines, such as Interleukin 4. Cytotoxic T cells, on
the other hand, express CD8+ on their surfaces (Taylor et al., 2012). Their primary role is
inducing cell apoptosis. They also excrete cytokines such as Interferon- γ and Interleukin2. Memory cells play a similar role to memory B cells to aid in a quicker immune response
to a pathogen. Regulatory T cells help maintain immunological tolerance and recognize
self (Ludwig-Portugall and Layland, 2012). Finally, the innate cells, such as NKT cells and
MAIT cells are associated with the bridging the adaptive and innate response. They can act
as T helper cells and T cytotoxic cells.
Helminth infections, have been typically associated with a Th2 cell response
(Taylor et al., 2012); however, while a Th2 is the primary response, it is an
oversimplification to classify it as solely a Th2. Response, as several more types of cells
and inflammatory markers are present in these more complex parasite interactions (Taylor
et al., 2012). To aid in differentiation of the different T cell types and stages, CDs are used,
as with B cells.
1.3.1.6 Immunoglobulins
There are a few different types of immunoglobulins (Ig), also known as antibodies,
involved in the immune response. In general, Igs are produced by plasma cells, although a
few of the aforementioned cell types may also produce small amounts (Baker et al., 2015;
Woof and Mestecky, 2015). They are highly specific, with each of the subclasses and
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isotypes performing a different function (Baker et al., 2015; Woof and Mestecky, 2015)..
The types and general function are in Table 1-4.
Table 1-4. Immunoglobulins produced in horses and their functions (Baker et al.,
2015; Woof and Mestecky, 2015).
Immunoglobulin Distribution Produced by
Acts upon
Function
IgA

Intravascular
and secretions

Plasma Cells

Mucosal
cells, enteric
pathogens

Protection of
mucus
membranes

IgD

Lymphocyte
surface

Immature B
lymphocytes

B cells,
Basophils,
mast cells

Unknown

IgE

Basophil and
mast cells

Plasma Cells

Eosinophils,
Basophils,
mast cells

Protection
against
parasites and
allergies

IgG

Intra- and
extra vascular

Plasma cells

Mast cells,
antigens,
initiating the
complement
pathway

Secondary
response,
innate,
humoral

IgM

Primarily
intravascular

Spleen;
plasma cells

Antigens,
activating the
complement
pathway

First response
innate
response,
humoral

33

1.3.1.7 Cytokines and chemokines involved in the immune
response
Cytokines and chemokines are essential for the host to defend itself from infections
and to recognize self. These are messengers between the immune cells (Meyer et al., 2016).
Table 1-5 highlights several important cytokines, including those in helminth infection and
mucosal barrier function.
Table 1-5. List of cytokines and their functions. Information taken from (Meyer et
al., 2016). Bold text indicates involvement with mucosal barrier, and goblet cell
function.
Main
producer(s):

Cytokine

IL-1

IL-2

•

•
•

IL-3

•
•
•

IL-4

•
•
•
•

Main Target(s)

•

•

Antigen
Presenting
Cells (APCs)
T cells

Activated
Th1 Cells
NK cells

•
•
•

B and
Eosinophils
T cells

•

Activated T
cells
Eosinophils
Mast cells

•
•
•

•

•

Basophils
Eosinophils
Hematopoietic
progenitor
cells
Mast cells

•
•
•

B cells
Eosinophils
Mast Cells

•

Macrophages

Activated
Th2 cells
Basophils
Eosinophils
Mast cells

•

•
•

•

•
•
•

•
•
•

IL-5

•
•
•

Eosinophils
Mast Cells
Th2 Cells

•

Eosinophils

Primary
Classification

Researched
in horses:

Role in
helminth
infections:

Acute
inflammation
Pyrexia
Stimulation of
APCs and T
cells

Proinflammatory

Yes
(Nielsen et
al., 2015)

Some
(Anuradha
et al., 2013)

Eosinophil
recruitment and
activation
Proliferation of
B and T cells

Proinflammatory

Yes
(Davidson
et al., 2002)

Yes (Turner
et al., 2013)

Decrease Th1
response
Eosinophil
recruitment and
activation
Increase IgE
Increase Th2
response

Proinflammatory

Yes (Janda
et al., 2015)

Yes (Svetić
et al., 1993)

B cell
proliferation
Mast cell
growth
Eosinophil
recruitment and
activation
Increased
mucin
production
and goblet
cells

Proinflammatory

Yes
(Davidson
et al., 2002;
Lanz et al.,
2013)

Yes
(Davidson
et al., 2002;
Lanz et al.,
2013)

Eosinophil
growth,

Proinflammatory

Yes
(Davidson
et al., 2002;

Yes (Allen
and
Sutherland,

Primary Function

•
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Main
producer(s):

Cytokine

Main Target(s)

Primary Function

Primary
Classification

recruitment,
and activity

Activated
Th2 cells
APCs
Somatic cells

•
•

•

Hematopoietic
cells

•

Bone
Marrow
Thymus

IL-8

•
•

Macrophages
Somatic cells

•
•

IL-9

•
•

Eosinophils
Th2 cells

IL-10

•

CD8+ B and
T cells
Macrophages
Activated
Th2 cells

IL-6

•
•
•

IL-7

•

•
•

•

•
•
•
•
•

B Cells
Dendritic
Cells
Macrophages
Monocytes
Th1 cells

Role in
helminth
infections:

Nielsen et
al., 2015)

2014;
LiconaLimón et
al., 2013)

Acute phase
response
B cell
proliferation
Increased IgE
T cell growth
Thrombopoiesis

Proinflammatory

Yes
(Nielsen et
al., 2015)

Yes
(Bazzone et
al., 2008)

•

T and B cell
Lymphopoiesis

Proinflammatory

Yes (Cook
et al., 2008)

Yes
(Wolowczu
k et al.,
1999)

Neutrophils
T cells

•

Chemotaxis

Proinflammatory

(Perkins et
al., 2008)

Yes (Singh
et al., 2013)

•

Hematopoietic
cells

•
•
•
•

Hematopoiesis
Lymphopoiesis
IgE production
Increase goblet
cell growth
and mucin
production

Proinflammatory

Yes
(Dewachi et
al., 2006)

Yes
(LiconaLimón et
al., 2017)

•
•
•

B Cells
Mast cells
T cells

•

Antibody
production
B cell
proliferation
Decrease mast
cell growth
Inhibits
cytokine
production

Antiinflammatory*

Yes
(Davidson
et al.,
2005a)

Yes
(LiconaLimón et
al., 2013)

Increased cellmediated
functions
Decrease Th2
response
Decreases IgE
production
Proliferation of
NK cells

Proinflammatory

Yes (Duran
et al., 2013)

Yes
(Setiawan
et al., 2007)

Proinflammatory

Yes
(Lawson et
al., 2019)

Yes
(Lawson et
al., 2019)

Proinflammatory

Yes (Page
et al., 2017)

Yes
(Serafini
and Di

B cells
T cells

•
•
•
•

•
•
•

IL-12

Researched
in horses:

•
•
•

B Cells
NK cells
T cells

•
•
•
•

IL-13

•
•
•
•

Basophils
Eosinophils
NK cells
Th2 cells

•
•
•

B cells
Eosinophils
Mast Cells

•
•

Same as IL-4
Increase goblet
cells and
mucin
production

IL-17(a)

•

Activated
CD4+ CD8+
memory
cells

•

Neutrophils

•

Neutrophil
recruitment
Activation of
epithelial,

•
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Main
producer(s):

Cytokine

Main Target(s)

Primary Function

Primary
Classification

Researched
in horses:

Role in
helminth
infections:

•
•
•

Monocytes
Neutrophils
T cells

IL-18

•
•

Macrophages
Th1 cells

•
•

NK cells
T cells

•

Induces IFN
production by T
cells and NK
cells

Proinflammatory

Yes
(O’Donova
n et al.,
2004)

Yes
(Helmby
and
Grencis,
2002)

IL-25

•
•
•
•

Granulocytes
Mast Cells
Th2 cells
Tuft cells

•
•
•

Eosinophils
Goblet Cells
Somatic cells,

•

Increases
cytokine
production
Increases
mucus
secretions
Potentiates
degranulation

Proinflammatory

No

Yes (Saenz
et al., 2010)

Promotes
accumulation,
proliferation,
and activation
in the tissues
Increases
cytokine
production

Proinflammatory

No

Yes (Saenz
et al., 2010)

Antiviral
effects
Decreases
eosinophil
counts, IgE and
Th2 response
Induces antigen
presentation
Promotes cellmediated
immunity

Proinflammatory

Yes
(Davidson
et al.,
2005a)

Yes
(Davidson
et al.,
2005a)

Cell death
Inflammation

Proinflammatory

Yes
(Davidson
et al.,
2005a)

Yes
(Davidson
et al.,
2005a)

•

•
•

IL-33

•
•

Epithelial
Cells
Myeloid
cells

•
•
•

Basophils
Dendritic
Cells
Mast cells

•

•

IFN- γ

•

Activated
Th1 and NK
cells

•
•
•
•

APCs
Macrophages
Neutrophils
Somatic cells

•
•

•
•

TNF- ⍺

•
•
•
•

Macrophages
Mast cells
NK cells
Th1 cells

•
•

APCs
NK cells

•
•

endothelial, and
eosinophil cells
Induces Mucin
5AC
production

Table 1-6. (continued)
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Santo,
2015)

1.3.1.8 Other markers of inflammation
There are several other markers that can be used to assess inflammation in horses;
Veterinarians use these blood markers in routine screenings for signs of inflammation, and
they are presented in Table 1-7.
Table 1-7. Blood markers used routinely by veterinarians for diagnosis of
inflammation in horses. Information sourced from (Stockham and Scott, 2008).
Factor
Produced by
Function
State in
Status in
inflammation cyathostomin
infections
Iron

Uptake from
diet

Transport
oxygen in red
blood cells

Decreased

Subtly
associated
(Andersen et
al., 2014)

Serum
Amyloid A
(SAA)

Liver

Acute phase
protein
produced in
response to
cytokines. A
potent
inflammatory
modulator

Increased

Not
Associated
(Andersen et
al., 2014)

Haptoglobin

Liver

Increased
inflammatory
reaction

Increased

Subtly
associated
(Andersen et
al., 2014)

Fibrinogen

Liver

Increased in
acute
inflammatory
disease

Increased

Subtly
associated
(Nielsen et
al., 2013;
Steinbach et
al., 2006)
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1.3.2 Equine Immune System in Parasitic Disease
Very little work has been done to date evaluating the equine immune system and
parasitic disease. This section summarizes what we know of cyathostomins and other
parasite infections in horses.
1.3.2.1 Responses to cyathostomins in vivo
For ease of breakdown, this section is further divided into the local and systemic
inflammatory responses in cyathostomin infections. Given the concern that anthelmintic
treatment may incite disease, many of the studies focus on these dynamic processes
following treatment.
1.3.2.1.1 LOCAL
Few studies have evaluated the local response and other processes to cyathostomins
within the tissues. In vitro work with these larval stages and adults has failed to yield high
numbers of worms and attempts to keep these alive have generally not been successful as
described in (Brianti et al., 2009). Therefore, at this time, the only option for studying these
aspects of the lifecycle are through terminal studies.
In 1999, Klei and Chapman reviewed all literature concerning cyathostomins and
the equine immune response. They reported the difficulties of establishing cyathostomin
infections in rodent or other models. They also focused on the evaluation of age-related
immunity. Older horses were reported to have lower FECs and worm burdens than younger
horses, illustrating that a more developed immune system, as seen in older horses,
decreases worm burdens and FEC output (Klei and Chapman, 1999). This was supported
by Monahan et al., who described that older horses, compared to younger horses, had lower
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mucosal larval burdens, specifically significantly lower EL3 burdens and slightly lower
LL3/L4s burdens (Monahan et al., 1998).
Du Toit et al. (2007) evaluated the role of mast cells and mast cell proteinases in
equine cyathostomin infections. They found that horses with encysted cyathostomin
infections had significantly more tryptase activity in the VC and DC than uninfected
horses. Also, the CEC of the horses expressed greater mast cell proteinase and had greater
toluidine blue uptake than the other organs and therefore exhibited greater mast cell activity
(du Toit et al., 2007). Pickles et al. (2010) also evaluated mast cells and their proteinases
in the ceca of adult horses. They found that higher mast cell counts were associated with
coinfection with A. perfoliata, but mast cell counts were not associated with proteinase
activity. In this study, higher cyathostomin counts, both luminal and mucosal exhibited
positive linear relationships with mast cell counts and their proteinases (Pickles et al.,
2010). Collobert-Laugier et al. found increased numbers of eosinophils and mast cells in
intestinal tissues with increased mucosal and luminal cyathostomin burdens. What they
found overall, however, was that the cellular populations differed with age. In younger
horses, there was a predominantly eosinophilic response, whereas older horses had a
greater mast cell response in the tissues (Collobert-Laugier et al., 2002), suggesting an age
related effect on the nature of the immune response.
When comparing larvicidal treatments, two studies have evaluated the mucosal
response at 2 weeks post treatment (WPT) in cyathostomin infections. Steinbach et al.,
noted a mild increased inflammatory response to the five-day dose regimen of FBZ
compared to moxidectin based on subjective histopathological findings (Steinbach et al.,
2006). In 2015, Nielsen et al., semi-quantitatively evaluated the local histopathologic and
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cytokine responses in horses treated with the larvicidal regimen of FBZ and MOX. While
all responses were subtle, it appeared that MOX treated horses had a greater inflammatory
response than the FBZ treated group, based on a greater cellular response and size of
inflammatory nodules surrounding the larvae.
Few studies have evaluated the cytokine expression within the wall of the large
intestine in horses with cyathostomin infection and disease. Davidson et al. (2005)
quantitatively evaluated the presence of cytokines in horses infected with the encysted
larval stages versus those that were not. They observed higher IL-4 expression with EL3
larvae in certain organs, such as the CEC compared to others; whereas other organs
expressed higher IL-4 with later stage larvae comparatively (Davidson et al., 2005). TNF⍺ was difficult to quantify, as it was expressed at low concentrations within the tissues. IL10 expression was significantly associated with EL3 and LL3/L4 larvae in the pelvic
flexure of the colon. IFN-γ was not significantly associated with the larvae. They concluded
that TNF-⍺ was associated with intestinal pathology, whereas the other cytokines appeared
to be involved with less pathology (Davidson et al., 2005). In horses with large intestinal
disease, they did not detect the presence of TNF-⍺ in horses with larval cyathostominosis
(Davidson et al., 2002). They also found the larval burdens and gross mucosal pathology
in larval cyathostominosis cases was most severe in the CEC and VC, where the greatest
worm burdens occur (Davidson et al., 2002).
1.3.2.1.2 SYSTEMIC
In 2002, Dowdall et al. harvested and isolated antigen from encysted and luminal
stages, to which they tested serum for IgG response to said antigens. They found that there
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was a significant IgG response in horses infected with cyathostomins and none in
uninfected controls; however, there was no association between the response and larval
and adult cyathostomin burden. They hypothesized that later stages produce greater
antigenic stimuli than early stages (Dowdall et al., 2002). Andersen et al. evaluated the
acute phase proteins in the blood following cyathostomin and S. vulgaris infections in
horses. This study reported possible hyperglobulinemia associated with parasitism in
horses (Andersen et al., 2014).
Another study evaluated systemic circulation of acute phase inflammatory proteins
and cytokines following treatment with moxidectin, pyrantel pamoate, or oxibendazole
(Nielsen et al., 2013). These studies evaluated SAA, fibrinogen, and haptoglobin, as well
as IL-1β, IL-4, IL-6 IL-10, IFN-γ and TNF-⍺. Minor increases in concentrations or
expression occurred throughout the study. The only statistical differences between
treatments occurred with fibrinogen, and, the only other factor contributing to statistically
significant differences was time (Nielsen et al., 2013).
Another study evaluated the proinflammatory response following treatment and
vaccinations in horses (Nielsen et al., 2015). While the data were not clear on the
interactions, it was found that following vaccination and anthelmintic treatment, a less
pronounced inflammatory response was produced (Nielsen et al., 2015). IL-10 was
generally expressed in higher quantities in horses treated with anthelmintics versus the
control group; however, IL-4 expression was highest in the untreated control group
(Nielsen et al., 2015). The findings may have indicated a lower inflammatory response
when anthelmintics were used in conjunction with vaccines; however, vaccine responses
were still within normal parameters across the groups (Nielsen et al., 2015). Another study
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evaluated the systemic response at two weeks post treatment in FBZ and MOX treated
ponies and found that no systemic differences occurred between the FBZ and MOX treated
groups and the horses in the untreated control group. There were no indications of a
difference in systemic inflammatory responses to treatment (Nielsen et al., 2015).
Finally, systemic cytokine responses have been evaluated in older and middle aged
horses (20-33 and 5-15 years old, respectively) following anthelmintic treatment with
either pyrantel pamoate or MOX (Adams et al., 2015). They found that older horses had
higher FECs and a more pronounced proinflammatory response to treatment than middle
aged horses. This was not attributed to the worm burdens of the horses, but rather to the
“inflamm-aging” phenomenon, where older horses have a greater inflammatory response
than younger horses (Adams et al., 2015).
1.3.2.2 Cyathostomin responses in vitro
Few attempts have been made to harvest excretory/secretory (E/S) antigens from
cyathostomins. For example, Paz-Silva et al. tested a liquid chromatography-based method
for isolating proteins from E/S products of infective L3 larvae; however, they were not
further classified or analyzed (Paz-Silva et al., 2011).
Another interesting study evaluated the stimulation of cyathostomin antigens on
peripheral blood mononuclear cells (PBMCs) from healthy horses and horses with
recurrent airway obstruction (RAO) (Lanz et al., 2013). They examined several cytokines,
including IL-4, IL-10, IL-13, and INF-γ. They found that there were significant differences
in IL-4 and Il-10 expression in those with RAO and those without RAO when exposed to
the antigen (Lanz et al., 2013).
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1.3.2.3 Immune reactions to other equine large intestinal
parasites
The immune reaction to Anoplocephala perfoliata in the large intestine has also
been evaluated. One study evaluated the effects of tapeworm antigen in vitro and the tissue
pathology and gene expression in vivo in horses (Lawson et al., 2019). They described
leucocyte and eosinophil infiltration and epithelial hyperplasia within the tissue
surrounding the ileocecal valve where the parasites were attached (Lawson et al., 2019).
They found a significant increase in IL-13 expression in these tissue samples, and a trend
toward (but insignificant) an increase in IL-4 production. IL-10 and IFN-γ expression was
lower in samples collected near the ileocecal valve (Lawson et al., 2019). When exposed
to the antigen in vitro, there was an increase in expression of IL-2, IL-4, IL-5, IL-13, and
IL-17 (Lawson et al., 2019).
1.4

Overview of Helminths and the immune system
1.4.1 Goblet Cells and Mucosal Barriers
Goblet cells are an integral part of the mucosal barrier of organs such as lungs,

stomach, and intestines. They are specialized cells within the epithelium that secrete
several products, including proteins and mucins, including mucus. Goblet cell hyperplasia
is noted in relation to parasite infections, including cyathostomins (Hasnain et al., 2010;
Ogbourne, 1978; Reynolds et al., 2012; Rodrigues et al., 2018).
Fallon et al., 2006 evaluated the role of IL-25 (IL-17E), a cytokine that drives the
Th2 response, compared to IL-17A, which is generally more involved with the Th1
response. They elucidated that IL-25 knockout mice failed to eradicate infections with N.
brasiliensis, a strongyle of rodents that is used extensively for hookworm models in
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humans (Fallon et al., 2006). This study also noted a decreased Th2 cytokine production,
specifically with IL-13 and IL-5 being produced at a fivefold lower level than in the wild
type mice; however, IL-4 was elevated at later timepoints. In this study, however, there
was no delay in GCH production. Once IL-25 was administered to these mice, a rapid
expulsion of the worms occurred; however, it was neither B nor T cell dependent. They
suggested that IL-25 may have another impact as to why GCH may have occurred without
the presence of worm expulsion, such as a lack of effect on intestinal contraction and
motility (Fallon et al., 2006).
In another study, IL-22 deficient mice infected with N. brasiliensis had delayed
worm expulsion, despite adequate Th2 cytokine response (Turner et al., 2013). This was
replicated with T. muris, where they also noted decreased GCH and delayed worm
expulsion in IL-22 deficient mice. This indicated its significant role of the mucosal
epithelial barrier in nematode infections in rodents (Turner et al., 2013).
Resistin-like molecule β (RELM-β) has been evaluated in nematode infections in
murine hosts. It is a product of goblet and epithelial cells and is implicated in
gastrointestinal immunity (Hogan et al., 2006). They found that RELM-β was a key
component of maintaining the mucosal integrity in inflammatory processes (Hogan et al.,
2006), and that it was essential in nematode clearance (Artis et al., 2004). In a Th2
response, RELM-β increased and helped induce a protective mucosal immunity, whereas
an IFN-γ and Th1 response decreased RELM-β expression and prolonged nematode
infections (Artis et al., 2004). Finally, IL-13 drove RELM-β expression in the intestines,
and RELM-β inhibited chemotaxic functions of nematodes in vitro (Artis et al., 2004).
Another goblet cell product is MUC2, a protein rich mucin excreted within the intestines,
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has been found to be upregulated in H. polygyrus infections, and directly involved in worm
expulsion in T. muris and N. brasiliensis (Hasnain et al., 2013a, 2013b; Reynolds et al.,
2012).
1.4.2 Other nematode models
Heligosomoides polygyrus is a rodent model parasite that is used routinely to
simulate small intestinal strongylid infections (Reynolds et al., 2012). They have a similar
lifecycle to cyathostomins where they migrate and encyst into the mucosa of the small
intestine (Reynolds et al., 2012) and have been successfully cultured in vitro to harvest
their E/S products (Reynolds et al., 2012). A combined T and B cell response was reported
to be necessary to adequately expel the worms in vivo (Reynolds et al., 2012). Another
study evaluated multiple infections of mice with H. polygyrus and found that a
compromised B cell function was not critical in expulsion of primary infections or
subsequent infections (Harris and Gause, 2011). Heligosomoides polygyrus also induces a
strong Th2 type response. In vitro studies have demonstrated an increase expression of IL4, IL-5, IL-9, and IL-10 from spleen and lamina propria cultured cells and IL-3, IL-4, IL5, and IL-9 from mesenteric lymph nodes and Peyer’s patches of the small intestine in vivo
(Finney et al., 2007; Reynolds et al., 2012; Setiawan et al., 2007; Svetić et al., 1993).
Studies have also found that IL-4 and, to a lesser extent IL-13, are the most critical for H.
polygyrus expulsion in mice (Reynolds et al., 2012).
In another rodent study with N. brasiliensis infections, IL-5, IL-13, IL-25, and IL33 were produced by epithelial cells in the lumen of the small intestine and excreted as an
alarm during damage to the tissue (Reynolds et al., 2012).
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1.4.3 Immune Modulation
Parasites produce excretory and secretory products, which are usually pooled
together as E/S antigens. These have been shown in several studies to modulate the host
parasite interaction, using many different mechanisms and proteins. This has been
comprehensively laid out by Hewitson et al. (2009) and provided in a brief summary in
Table 1-8.

Briefly, there are many types of immunomodulation used by cestodes,

trematodes, and nematodes to allow them to parasitize the host (Hewitson et al., 2009).
These allow for cell inhibition or proliferation and recruitment and/or decrease in
inflammatory response (Hewitson et al., 2009).
Table 1-8.Types of E/S products. Produced by helminths, as presented by Hewison
et al., 2009. None of these have been evaluated in cyathostomin infections.
E/S Product type

Helminth
identified in:

Target(s)

Alpha-1 and omega1

Trematode
(Schistosomes)

Basophils

•
•
•

Glycoproteins

Trematodes

Varies. Can
include DCs

•

Nematodes

Function(s)

•
•

Cytokine
homologues

Trematodes

Varies.

•

Cestodes
•
•

Nematodes
C type lectins and
galectins

Nematodes
(filariids,
ascarids,
strongylids)

Varies (T
cells)

•
•

Protease inhibitors
(Cystatins, serpins)

Nematodes

Varies

•
•
•
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Pro/antiinflammatory

Degranulation
IL-4 production
Induction of Th2
Response
Induce Th2
response
Granuloma
formation
Induce IL-10
production
Induce proinflammatory
response
IL-4
Generation of
Treg cells
Immune evasion
Eosinophil
chemoattractant

Proinflammatory

Reduced antigen
presentation
Reduced T cell
priming
Increase IL-10
production

Antiinflammatory

Proinflammatory
(in general)

Proinflammatory

N/A
Evasion

Antioxidants and
acetylcholinesterases

Trematodes

Varies

•

Nematodes
•
•

Venom allergen,
associated secreted
protein (ASP)

Nematodes

Varies

•

Neutrophils
•
•

Novel proteins

Trematodes

Varies

Nematodes

•
•

Induction of
alternatively
activated
macrophages
Decreases
phagocytosis
and oxidation
Decrease
parasite
clearance
Inhibit
neutrophil
function
Chemokine like
functions
Neutrophil
chemotaxis
Impairs cell
signaling
Decreased Th1
responsiveness

Both

Antiinflammatory

Antiinflammatory or
Unknown

Table 1-9. (continued)
1.5

Aims and hypotheses
•

H1: Equids that receive anthelmintic treatment will have a lower local and
systemic inflammatory responses than equids that do not

•

H2: MLs will have a greater inflammatory response than BZs due to their
higher efficacy and removal of larger encysted and luminal cyathostomin
burdens

•

H3: Larvicidal treatment will incite a greater inflammatory response from
encysted and luminal worm die-off than non-larvicidal treatment

•

H4: A greater cyathostomin burden, both mucosal and luminal, will decrease
the proinflammatory response

•

H5: Encysted cyathostomins will be able to potentiate an anti-inflammatory
response
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•

H6: Local inflammatory responses to treatment will appear in systemic
circulation as “spillover”

The aims of the following studies are to evaluate the local and systemic
immunologic responses in naturally acquired cyathostomin infections across extended
timepoints (2 and 5 weeks post treatment), specifically after receiving anthelmintic
treatment. Another goal is to characterize the inflammatory response and role of goblet
cells in cyathostomin infections and following anthelmintic treatment. Finally, a third aim
is comparing the inflammatory response to benzimidazoles versus macrocyclic lactones,
and larvicidal versus non-larvicidal effects at extended timepoints.
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CHAPTER 2. EVALUATION OF THE MUCOSAL INFLAMMATORY RESPONSES
TO EQUINE CYATHOSTOMINS IN RESPONSE TO TREATMENT
THIS RESEARCH WAS ORIGINALLY PUBLISHED IN VETERINARY IMMUNOLOGY AND
IMMUNOPATHOLOGY 199, 1-7.
2.1

Introduction
Equine cyathostomin parasites are omnipresent in grazing horses across the world,

and infection is virtually inevitable. This group of parasites consists of 14 genera and 50
species, of which 8 genera and 40 species are described infecting horses (Lichtenfels et al.,
2008). The life cycle is unique among strongylids, as cyathostomin larvae are known to
undergo arrested development at the early third larval stage (EL3) (Eysker and Mirck,
1984), where hundreds of thousands of larvae can accumulate over time, presumably under
the influence of a host response to the invading larvae (Chapman et al., 2003). Furthermore,
EL3 counts have been reported to be significantly higher during seasons characterized by
weather conditions that are unfavorable for parasite transmission on pasture (Chapman et
al., 2003; Eysker et al., 1990; Ogbourne, 1975). Larvae eventually mature into late third
(LL3) and fourth (L4) stages before they leave their cysts and make their way back to the
intestinal lumen. This process has been associated with a pronounced inflammatory
reaction, and when large numbers of larvae emerge synchronously, it can cause a severe
typhlocolitis known as larval cyathostominosis (Love et al., 1999). While the disease
complex is well described, the local inflammatory and immunologic mechanisms are
poorly understood.
Of the current marketed equine anthelmintics, only fenbendazole (10 mg/kg or 7.5
mg/kg) administered orally once daily for five consecutive days and moxidectin gel (0.4
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mg/kg) administered once orally are labeled for use against encysted cyathostomins. Of the
two treatments, cyathostomins have documented resistance to the adulticidal dose of
fenbendazole, as well as the other benzimidazoles (Kaplan et al., 2004; Lester et al., 2013;
Peregrine et al., 2014) and the larvicidal dose regimen (Bellaw et al., 2018; Reinemeyer et
al., 2015).
When considering the inflammatory response to treatment, one study suggested a
significantly reduced local inflammatory response in ponies treated with moxidectin
compared to the five-day fenbendazole regimen (Steinbach et al., 2006). We recently
evaluated local and systemic inflammatory markers in response to moxidectin and the
larvicidal regimen of fenbendazole and found no systemic responses to any of the two
treatments (Nielsen et al., 2015). Locally, subtle inflammatory reactions were associated
with moxidectin treatment but not fenbendazole treatment; however, this was largely
contributed to the reduced larvicidal efficacy of fenbendazole (M. K. Nielsen et al., 2015).
Recently, we completed another treatment trial comparing the larvicidal effects of
the five-day fenbendazole treatment regimen (n=12) with moxidectin (n=12) and an
untreated control group (n=12). In addition, to comparing the larvicidal efficacy of these
two anthelmintic formulations, we also evaluated two different time intervals between
treatment and necropsy; 2 weeks and 5 weeks. Anthelmintic efficacy results from this study
are presented elsewhere (Bellaw et al., 2018). Overall, mucosal worm burdens were
substantially higher than in the previous study (Reinemeyer et al., 2015), but the 2-week
post treatment larvicidal efficacies were very similar with reduced larvicidal efficacy of
the fenbendazole regimen (50.4%), whereas moxidectin efficacy (73.8%) was within
historically reported ranges (Bellaw et al., 2018).
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The aims with the present study were to collect further histopathological
information on local inflammatory responses to anthelmintic therapy and perform the first
comparison of histopathological reactions observed at the two different time intervals post
anthelmintic treatment.
2.2

Materials and Methods
2.2.1 Study Design
The University of Kentucky’s Institutional Animal Care and Use Committee

approved this study, protocol number 2015–2092. The study was carried out between
September and October of 2015. Thirty-six ponies ranging from two to four years of age
with naturally acquired cyathostomin infection were kept on pasture throughout the study.
Ponies were blocked into groups of three based off age and decreasing magnitude fecal egg
counts (performed with mini-FLOTAC, detection limit of 5 eggs per gram Barda et al.,
2013). One pony from each block was randomly allocated into one of three treatment
groups: fenbendazole treated, and moxidectin treated, and untreated control groups.
Twelve ponies were allocated into each of the 3 treatment groups. All study personnel were
blinded to group allocation and treatments throughout the study.
On Day-1, each pony was weighed on a certified livestock scale and individual
doses of larvicidal anthelmintic were prepared based off weight and group assignment.
Ponies assigned to the fenbendazole treatment group received 10 mg/kg fenbendazole
(Panacur PowerPak, Merck Animal Health, Madison, NJ, USA) for five days, Days 0–4.
Ponies assigned to the moxidectin treatment group received 400 μg/kg of moxidectin
(Quest, Zoetis, Kalamazoo, MI) orally once on Day 4. On Days 18 and 19 (2 weeks post
treatment), three ponies randomly selected from each group were necropsied and tissues
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samples taken. Three complete replicates were necropsied each day to ensure that equal
numbers of ponies from each treatment group were necropsied simultaneously. The rest of
the 18 ponies were kept on pasture until Days 35 and 36 (5 weeks post treatment), when
they were euthanized, and tissue samples were taken.
2.2.2 Histology
Tissue samples of approximately 2.5cm were collected from grossly normal
appearing middle portions of the cecum, ventral colon and dorsal colon. The samples were
stored in 10% formalin for 24h then transferred to 70% ethyl alcohol until use for
histopathology purposes. These tissue samples were routinely processed and stained with
Harris hematoxylin and eosin. All samples were analyzed by light microscopy and
immunohistochemistry as previously described (Nielsen et al., 2015). In summary, larvae
were evaluated based on size and morphological characteristics to determine larval stage
(L3 or L4). Lesions associated with 3rd and 4th stage cyathostomin larvae were counted
and histologically assessed for location (colonic glands, mucosal epithelium, lamina
propria, or submucosa), size, inflammatory cell composition (neutrophils, eosinophils,
macrophages, and lymphocytes), and severity of inflammation and fibrosis (0=none; 1=1–
5 cell layers, mild inflammation or fibrosis; 2=6–15 cell layers, moderate inflammation or
fibrosis; or 3= >15 cell layers, severe inflammation or fibrosis). Additionally, tissue
sections were analyzed for the presence or absence of goblet cell hyperplasia, mucosal
ulceration, and submucosal granulomas.
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2.2.3 Immunohistochemistry
Immunohistochemistry was utilized to characterize the mononuclear leukocyte
population. Tissue sections were immunohistochemically stained (Dako, EnVision+Dual
Link System-HRP) for Cluster of differentiation 3 (CD3) (Dako polyclonal rabbit
antihuman CD3, Code A0452), CD20 (Thermo Scientific rabbit polyclonal antibody,
Catalog

#RB-9013),

and

MAC387

(Dako

monoclonal

mouse

anti-human

Myeloid/Histiocyte antigen, clone 387) to quantify T cells, B cells, and activated
macrophages, respectively. The number of immunohistochemically stained cells were semi
quantitatively graded (0=none; 1=1–5 cell layers; 2=6–15 cell layers; or 3= >15 cell layers)
for the radius of each parasite associated inflammatory focus.
2.2.4 Statistical analyses
All statistical analyses were carried out using SAS University Edition (SAS
Institute, Cary, NC, USA). Generalized mixed linear models were developed to analyze
the effects of treatment groups and weeks post treatment on the histopathological findings.
Inflammatory nodule radius size and total mucosal length were the only continuous
variables, while all others were labeled as categorical variables. Horse ID was kept as a
random effect. Models were generated to analyze cell counts, larval counts, goblet cell
hyperplasia, mucosal ulcerations, and inflammatory nodules with and without parasites.
L3s, L4s, and degenerative larvae were evaluated in the cecum, ventral colon, and dorsal
colon in respect to their locations in the submucosa, lamina propria, and mucosa. For all,
‘organ’ and ‘location’ were covariates. Total length of the organ mucosa of all samples of
all groups was analyzed for possible bias as well. Influence of all measured parameters for
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each analysis was evaluated using traditional backward and forward elimination of
variables. All variables with p-values<0.25 were kept in the model. The interaction
between ‘groups’ and ‘weeks post treatment’ was also evaluated in each analysis. When
variables were significant, a ‘least square means’ for a Tukey’s pairwise comparison, odds
ratio, and estimate were all performed, and interpretation of results occurred at the
significance level α=0.05.
2.3

Results
2.3.1 Worm Burdens
Bellaw et al., 2018 published the mean worm burden of these ponies Table 2-1.

Postmortem mean luminal adult worm and larval counts, as well as the mean encysted
larval counts from the three groups. Data taken From Bellaw et al. 2017. Briefly, all
luminal worm burdens increased from 2 to 5 weeks post treatment, with the exception of a
decrease of luminal L4s in the control group. All encysted stages decreased from 2 to 5
weeks post treatment across all groups. The average larval counts per 50mm of tissue
evaluated is included as Table 6-1.
Table 2-1. Postmortem mean luminal adult worm and larval counts, as well as the
mean encysted larval counts from the three groups. Data taken From Bellaw et al.
2017.
Group
Weeks Post
Luminal
Luminal L4
EL3
LL3/L4
Treatment
Adult
Fenbendazole

Moxidectin

Control

2

10,750

4,608

77,436

32,226

5

62,873

20,136

31,333

8,000

2

1,150

1,371

40,900

28,000

5

17,240

12,016

18,200

9,200

2

147,869

78,991

156,000

110,200

54

5

62,705

9,745

64,571

9,286

Table 2-2. (continued)

2.3.2 Macrophages
Total macrophage score differences between groups were significant
(p=0.05), with moxidectin treatment group having a higher mean macrophage score than
the fenbendazole treatment group (p<0.0185), in which scores only ranged between 0 and
2 (Figure 2-1a). Degenerative larvae were associated with a higher macrophage score than
L3s and L4s, and L4s were associated with a higher score than the L3 stages (p<0.05)
(Figure 2-2). Significantly more activated macrophages (MAC387-positive) were found in
the control untreated group than the fenbendazole and moxidectin groups (p<0.0104, and
p<0.0004), in which scores ranged from 0 to 2, and the untreated control group’s scores
ranged from 0 to 3 (Figure 2-3a). There were significantly more activated macrophages
associated with inflammatory nodules in the ventral colon than the dorsal colon and lower
numbers in the lamina propria than the submucosa (p<0.0004). The average macrophage
scores and activated macrophage scores at the two time points per group is presented in
Supplemental Figure 2-1.
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Figure 2-1. Box-whisker plots representing inflammatory cell scores(0 = none; 1 = 15 cell layers, mild inflammation or fibrosis; 2 = 6-15 cell layers, moderate
inflammation or fibrosis; or 3 = >15 cell layers, severe inflammation or fibrosis) and
lesion size (mm) in the three treatment groups. Upper and lower bounds of the box
represent the upper and lower quartile, respectively. The diamond represents the
mean of the observations and the whiskers represent the minimum and 362
maximum observations per group. Asterisks indicate a statistically significant
difference between the groups (p<0.05). a) macrophage scores, b) lymphocyte
scores, c) neutrophil scores, d) eosinophil scores, e) fibrous connective tissue scores,
f) inflammatory nodule size radius size, g) granuloma nodule size radius, h) goblet
cell hyperplasia scores.
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Figure 2-2. Histopathology sections of representative findings. The size bar in all
sections except d is equal to 100μm. a) Dorsal colon with goblet cell hyperplasia
score of 0 (100x, H&E). Moxidectin group 5 weeks post treatment. b) Ventral colon
with goblet cell score of 2 (100X, H&E). Control group 5 weeks post treatment. c)
Dorsal colon with L3 larva in the submucosa surrounded by a large population of
inflammatory cells and fibrous connective tissue (100X, H&E). Moxidectin group 2
weeks post treatment. d) L3 larva in the glands of the cecum surrounded by a thin
layer of inflammatory cells and fibrous connective tissue (400X, H&E scale bar is
40μm). Control group 2 weeks post treatment. e) Cecum with degenerative L4 larva
in the submucosa (200X, H&E), surrounded by degenerative eosinophils, fibrous
connective tissue, and inflammatory cells. Fenbendazole group 2 weeks post
treatment. f) Intact L4 larva in the mucosa of the cecum, control group 2 weeks post
treatment (100X, H&E). g) Intact L4 larva in the submucosa of the cecum (40X,
H&E). h) Ventral colon with CD20-positive B lymphocytes (100X), representing a
lymphocyte score of 3. Moxidectin group 2 weeks post treatment. The arrow
identifies a large aggregate of B lymphocytes.

Figure 2-3. Box-whisker plots of the immunohistochemically (IHC) stained cell
scores per treatment group. Upper and lower bounds of the box represent the upper
and lower quartile, respectively. The diamond represents the mean of the
observations and the whiskers represent the minimum and maximum observations
per group. Asterisks indicate a statistically significant difference between the groups
(p<0.05). a) MAC387-positive activated macrophage scores. b) CD20-positive B
lymphocyte scores. c) CD3-positive T lymphocyte scores.
2.3.3 Lymphocytes
Total lymphocyte population did not differ between treatment groups (Figure 2-1b).
In the CD20-positive B lymphocytes, scores ranged from 0 to 3 in all treatment groups and
there were no statistical differences between the groups (Figure 2-3b). Significantly more
B lymphocytes were in inflammatory nodules in the mucosa than in the lamina propria and
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submucosa (p<0.05) (Figure 2-2). CD3-positive T lymphocytes were elevated in the
moxidectin group when compared to the control group (Figure 2-3c). T cell scores were
also elevated in the mucosa when compared to the submucosa (Table 2-3). The lymphocyte
scores, B lymphocyte scores, and T lymphocyte scores at the two time points per group are
presented in Supplemental Figure 2-1.
Table 2-3. P values of response variables tested in the mixed linear models and the
input variables given in the analysis. Dashed lines indicate variables not included in
the model.
Response
variable

Grou
p

Weeks
Post
Treatment

Sample

Location

Larval
Stage

Macrophages

Neutrophils

Eosinophils

Lymphocytes

Inflammatory
Nodule Size
radius

Fibrous
Connective
Tissue

Eosinophils
Neutrophils
Macrophages
Lymphocytes

>0.25
>0.25
0.05
>0.25

0.0497
0.1895
0.1929
>0.25

>0.25
>0.25
>0.25
>0.25

>0.25
0.1103
>0.25
0.105

<.0001
>0.25
<0.0001
0.047

0.0062
>0.25
0.0047

>0.25
0.0362
>0.25

>0.25
0.0528
<0.0001

<.0001
0.016
<0.0001
-

<.0001
>0.25
0.0003
<0.0001

>0.25
>0.25
>0.25
0.1271

Larval Stages

0.104

>0.25

0.0019

<0.0001

-

>0.25

>0.25

0.0193

>0.25

0.0356

0.0357

Fibrous
Connective
Tissue

>0.25

0.0014

0.1058

0.0013

0.1006

>0.25

>0.25

>0.25

>0.25

>0.25

-

B lymphocytes

>0.25

>0.25

>0.25

0.0002

>0.25

>0.25

>0.25

>0.25

>0.25

>0.25

>0.25

T Lymphocytes

0.025

>0.25

0.0769

0.0219

0.1403

>0.25

>0.25

>0.25

>0.25

>0.25

>0.25

Activated
Macrophages

0.001

>0.25

0.0409

0.0004

>0.25

>0.25

>0.25

>0.25

>0.25

>0.25

>0.25

Goblet Cell
Hyperplasia

0.182
8

0.0047

0.0032

>0.25

>0.25

-

-

-

-

-

-

Inflammatory
Nodule Size
Radius

>0.25

>0.25

>0.25

0.0672

0.0003

0.0027

0.0793

0.0001

0.0003

-

>0.25

L3s

>0.25

>0.25

>0.25

>0.25

>0.25

>0.25

>0.25

>0.25

>0.25

>0.25

0.0009

0.0047

>0.25

>0.25
***<0.2
5

>0.25

**L4s

-

-

-

-

-

-

Degenerative
Larvae

>0.25

>0.25

>0.25

>0.25

>0.25

>0.25

>0.25

>0.25

>0.25

>0.25

>0.25

Mucosal
Ulcerations

>0.25

>0.25

>0.25

>0.25

>0.25

>0.25

>0.25

>0.25

>0.25

>0.25

>0.25

Submucosal
Granulomas

0.122
9

0.1131

>0.25

>0.25

*0.0028

0.0396

>0.25

>0.25

0.1108

-

0.1708

* L4s in the submucosa
** L4s in the mucosa
***difference values between the larval stages in the model

2.3.4 Neutrophils
Neutrophils had no significant difference among groups, weeks post treatment,
organ (cecum, dorsal colon, and ventral colon), location or with larval stages (Figure 2-1c).
The neutrophil scores at the two time points per group are presented in Supplemental Fig.
2.1.
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2.3.5 Eosinophils
Eosinophil scores were elevated at 2 weeks post treatment versus 5 weeks post
treatment and were elevated across all groups (Table 2-3); however, no difference was seen
between treatment groups (Figure 2-1d). Eosinophil scores were also higher in the presence
of degenerative larvae than both L3 and L4 larvae and higher scores were associated with
L4s than L3s (p<0.05). The eosinophil scores at the two time points per group are presented
in Supplemental Figure 2-1. The average eosinophil scores per organ per time point per
group are presented in Supplemental Table 2-2.
2.3.6 Goblet Cells
Goblet cell hyperplasia scores were elevated at 5 weeks post treatment compared
to 2 weeks post treatment across all groups (Figure 2-1h) and were also elevated in the
ventral colon in comparison with the dorsal colon (Table 2-3); however, no statistical
difference was noted between the ventral colon and the cecum. The goblet cell hyperplasia
scores at the two time points per group are presented in Supplemental Figure 2-1. The
average goblet cell hyperplasia scores per organ per time point per group are presented in
Supplemental Table 2-2.
2.3.7 Larvae
When multiple stages of larvae were present in a sample, no statistical significance
was apparent between the larval stages present. The number of intact L4s in the mucosa
varied significantly by weeks post treatment, with greater numbers of L4s being present at
two weeks versus five weeks (Table 2-3). The dorsal colon contained fewer L4s than the
cecum and ventral colon (Table 2-3). Larvae were surrounded by variably sized
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inflammatory nodules ranging from 0.01 to 1.13mm, with no statistically different radii
between groups (Figure 2-1g, Figure 2-2, and Table 2-3).The fibrous connective tissue
scores (FCT) were significantly elevated in the submucosa when compared to the lamina
propria (p<0.0003). Fibrous connective tissue scores were also significantly lower at 5
weeks post treatment than 2 weeks post treatment (Table 2-3). Mucosal ulcerations were
noted only in the control group at 2 weeks post treatment. Submucosal granulomas ranged
in size from 0.1 to 1.65mm and there were no statistical differences in the number of
submucosal granulomas between the groups (Figure 2-1f). The larval counts at the two
time points per group are presented in Supplemental Figure 2-1.
2.4

Discussion
This study is the first to characterize the local inflammatory response at both 2- and

5-weeks post treatment, as well as further characterize the local inflammatory response to
the parasites themselves and to the treatments. While there were subtle differences between
treatment groups, this study determined several novel findings among the treatment and
control groups not previously reported.
In previous studies, goblet cell hyperplasia had been noted (Nielsen et al., 2015;
Steinbach et al., 2006); however, it had not been found to be statistically significant
between weeks post treatment, organ, or negatively associated with encysted worm burden.
In the present study, goblet cell hyperplasia varied by weeks post treatment and the organ
it was located in. Scores were elevated at five weeks post treatment when compared to two
weeks post treatment, and scores were higher in the ventral colon than the cecum and dorsal
colon. As these observations were made amongst all treatment groups, including the
control group, it is unlikely that this is treatment related and it may instead be related to
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seasonality, infection pressure, or stage of infection. It may also be hypothesized that the
significantly lower larval counts and luminal worm counts observed at five weeks post
treatment (Bellaw et al., 2018) may be due to an increased goblet cell reaction and resulting
in worm expulsion; however, more work is needed to understand the role of goblet cell
hyperplasia in luminal as well as encysted cyathostomin infections. In other species, such
as rodents, interleukins (IL) 4 and 13 serve a large role in worm expulsion and are the
primary drivers of goblet cell hyperplasia induction from intestinal epithelial cells (Fallon
et al., 2006). In rodents experimentally infected with Nippostrongylus brasiliensis and
Heligosomoides polygyrus, members of the order Strongylida (where H. polygyrus
possesses a life cycle similar to cyathostomins, in that the larvae encyst in the mucosa of
the small intestine), it was found that these goblet cells upregulated Resistin-Like Molecule
beta (RELM-β) in response to infection, after migration of the worms to the small intestine.
It was also noted that RELM-β knockout mice had prolonged infection times, suggesting a
role of RELM-β in the expulsion of adult N. brasiliensis and H. polygyrus infections, but
not in the larval encysted forms of H. polygyrus (Herbert et al., 2009). In another study,
upregulation of Mucin 5AC (MUC5AC) in cecal goblet cells during Trichuris muris
infection was found necessary for worm expulsion (Hasnain et al., 2011). Overall, it has
been shown in other species that the regulation of goblet cell hyperplasia is mediated by
IL-4 and IL-13 and leads to the upregulation of important components for worm expulsion.
To date, limited work has been done with IL-4 and IL-10 in equine cyathostomin infections
(Davidson et al., 2005b; M. K. Nielsen et al., 2015) and the connection between these
cytokines and goblet cell hyperplasia has not been established. Currently, no work has been
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done with cyathostomin parasites in regard to IL-13 and MUC5AC/RELM-β, and this
remains a path for future investigation.
The overall macrophage scores of the fenbendazole group were significantly lower
than those of the moxidectin group, and the mean scores of the activated macrophage a
significant difference between the control and the two treatment groups in the mean
activated macrophage scores, suggesting a difference in the inflammatory response
between the two treatment groups (Figure 2-3a). It could be inferred that the lower
macrophage scores in the fenbendazole group could be due to the lack of efficacy reported
by Bellaw et al., (2018). While there were no overall differences in the total lymphocyte
population (Figure 2-1b), the treatment groups had significantly more T lymphocytes than
the untreated control group (Figure 2-3c). Anthelmintic treatment may upregulate the
immune response in regard to the T lymphocyte pathway; however, future studies are
needed to evaluate this potential role of immunoregulation. In total, these inflammatory
cell findings differ somewhat from two previous studies, where inflammatory responses
were only noted to one of the two treatments evaluated; moxidectin (Nielsen et al., 2015)
or fenbendazole (Steinbach et al., 2006).
The finding of intact L4s in the mucosa varied by weeks post treatment, with a
large number being present at two weeks compared to the five week time point (Table 2-3);
this is in accordance with mucosal digest data generated in the same study (Table 2-1;
Bellaw et al., 2018). The cecum and ventral colon contained more L3s and L4s than the
dorsal colon, which is also in agreement with previously reported counts determined with
a mucosal digest method (Bellaw et al., 2018; Reinemeyer and Herd, 1986). The larvae
(L3 and L4) were also more likely to be encysted in the mucosa, specifically in the lamina
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propria, than in the submucosa. Steinbach et al. (2006) also reported that the majority of
all larvae were more likely to encyst in the lamina propria and mucosa; however, these
authors also indicated that the majority (67–90%) of L4 larvae encysted in the submucosa
in all treatment groups. Taken together, these two studies suggest that larval populations
may prefer to encyst in the mucosa over the submucosa. It is also hypothesized that the L3s
may not have persisted long enough to stimulate a larger host response around the
individual larvae in the form of fibrous connective tissue or increased inflammatory cells
(Table 2-3) or that they may be less immunogenic. Mucosal ulcerations were only found
in the control group which differs from Steinbach et al. (2006), where ulcerations were
found only in fenbendazole treated groups.
In summary, there were subtle differences in the inflammatory response between
treatment groups. However, both treatment groups had elevated T cells in comparison to
the control group, and the fenbendazole group had significantly lower macrophage scores
than the control group. It is also worth noting that some lesions, such as mucosal
ulcerations, were solely noted in the untreated control group. Furthermore, an increase in
goblet cell hyperplasia scores was observed between the two time points, coinciding with
decreased encysted larval counts and further investigation can shed more light on these
processes.
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CHAPTER 3. CYTOKINE AND GOBLET CELL GENE EXPRESSION IN EQUINE CYATHOSTOMIN
INFECTION AND LARVICIDAL ANTHELMINTIC THERAPY

THE FOLLOWING CHAPTER WAS PUBLISHED IN PARASITE IMMUNOLOGY. 2020. 00:E12709
LICENSE NUMBER FOR REUSE IN DISSERTATION: 4793690425223
Abstract
Aims: The role of the immune response to cyathostomin infections in horses
remains unknown. Intestinal goblet cell hyperplasia has previously been noted as a
component in cyathostomin infection; however, the function is unclear. The goal of this
study was to evaluate the local and systemic gene expression to cyathostomin infections
following larvicidal treatment and explore their relation to goblet cells. Methods and
results: 36 ponies with naturally acquired cyathostomin infections were randomly allocated
into 3 groups: fenbendazole-treated (10mg/kg PO 5 days), moxidectin-treated (0.4mg/kg
PO once), and untreated control. Whole blood from all horses was collected weekly, and
tissue samples from the large intestine collected during necropsy at 2- and 5-weeks post
treatment (WPT). Gene expression of interleukin (IL)-4, IL-5, IL-6, IL-10, IL-13, IL-17A,
IL-22, IFN-γ, Resistin-like Molecule beta (RELM-β), Mucin 2 (MUC2), and Tumor
Necrosis Factor (TNF)-α was measured using qRT-PCR. There were statistically
significant linear correlations between luminal worm burdens and MUC2 (r= -0.2358) and
RELM-β (r= -0.2261). Conclusion: This suggests an active role of immune system post
treatment in parasite expulsion, specifically in goblet cells, and that the organs respond
differently to treatment and the larvae themselves. This may have implications in the
disease process and treatment.
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3.1

Keywords
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anthelmintic
3.2

Introduction
Domestic horses are hosts to a plethora of parasites, including cyathostomins, a

group of parasites composed of 8 genera and 40 species infecting domestic horses alone
(Lichtenfels et al., 2008). Cyathostomins are pervasive parasites of horses, and their
lifecycle is unique among strongylids. After ingestion of the infective 3rd larval stage (L3),
the Early 3rd larval stages (EL3) encyst in the mucosa of the dorsal and ventral colons (DC
and VC, respectively), as well as cecum (CEC), where they can undergo hypobiosis for up
to 2 years (Ogbourne, 1975). The larvae proceed to develop into Late 3rd larval stage
(LL3s) and mucosal 4th larval stage (L4s). All mucosal stages are collectively referred to
as developing larvae (Eysker and Mirck, 1984). The L4s then emerge into the intestinal
lumen to molt to the adult stages and complete the lifecycle. In rare cases, the emergence
of the L4s from the mucosa to the lumen of the large intestine causes larval
cyathostominosis, a life-threatening disease. The mass emergence of larvae leads to an
acute or chronic generalized typhlocolitis and protein-losing enteropathy as well as
secondary bacterial infections (Love et al., 1999). This disease is reported to be fatal in
50% of cases and reported risk factors include recent treatment with a non-larvicidal
anthelmintic, horse age (2-5 years of age), and season (such as autumn or winter) (Reid et
al., 1995).
Considerable inflammation is associated with the encysted EL3s, LL3s, and
L4s, as well as profound, diffuse inflammatory reactions associated with the process of
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excystment of the L4s into the lumen (Love et al., 1999). Few studies describe the disease
process and evaluate the mechanisms and inflammatory reactions associated with the
progression of parasitic stages, as well as from these parasites in response to both larvicidal
and nonlarvicidal treatment. Davidson et al. evaluated the local tissue gene expression
levels of Interleukin (IL)-4, IL-5, IL-10, Interferon (IFN)-γ, in large intestinal tissues with
and without encysted larvae present (Davidson et al., 2005). Tissues with encysted
cyathostomins present expressed higher levels of IL-4, IL-5, and IL-10 than those without,
whereas expression of IFN-γ did not differ between the two groups; however, the study did
not evaluate other cytokines or genes involved in the Th1 and Th2 immune responses
(Davidson et al., 2005). Only one study thus far has evaluated cytokine gene expression in
intestinal tissues in horses with and without large intestinal disease, including three larval
cyathostominosis cases (Davidson et al., 2002). This study found Tumor Necrosis Factor
(TNF)-α was expressed in horses with inflammatory bowel disease, and less likely to be
expressed in cases of larval cyathostominosis and those without parasites; however, there
were no significant differences between the groups with and without large intestinal
disease, including those with encysted cyathostomins present (Davidson et al., 2002). The
study did not quantify the gene expression of the cytokines present, and further
investigation is warranted to evaluate quantitative differences that may occur in parasitic
disease and at various stages of cyathostomin infection, as well as following anthelmintic
treatment.
Currently, there are two anthelmintic products labeled for larvicidal
treatment of encysted cyathostomin larvae: fenbendazole (10 mg/kg or 7.5mg/kg orally for
5 consecutive days) and moxidectin (0.4 mg/kg orally once). Studies have described the
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inflammatory response to these two larvicidal treatments both locally and systemically
((Nielsen et al., 2015; Steinbach et al., 2006; Steuer et al., 2018). While these studies
evaluated the inflammatory response to the larvae and treatment, their scope of testing of
the inflammatory response (especially in regard to the local cytokine and local gene
expression) was limited. Based on histopathological evaluation of local tissue reaction,
Steinbach et al. concluded that there was substantially more inflammation in the
fenbendazole-treated group compared to the moxidectin group (Steinbach et al., 2006). In
comparison, we have reported only subtle differences in local pro-inflammatory cytokine
gene expression between groups of horses treated with the same anthelmintics ((M. K.
Nielsen et al., 2015). Most recently, we evaluated the histopathologic effects of both
moxidectin and five-day fenbendazole-treatment over two post treatment time intervals,
and noted inflammatory reactions both at 2 and 5 weeks post-treatment (WPT) (Steuer et
al., 2018). One of the primary novel findings was the correlation of goblet cell hyperplasia
with decreased mucosal larval and luminal worm counts at 5 WPT (compared to 2 WPT)
across all groups, including the untreated controls (Steuer et al., 2018). This suggests a
process of worm expulsion from the mucosa occurring, regardless of anthelmintic
treatment. Goblet cells are an integral part of the epithelial barrier of organs and produce
mucin products. Goblet cell hyperplasia has been observed in concordance with worm
expulsion in other animal species, and the process involves IL-4, IL-13, and upregulation
of Resistin-Like Molecule (RELM)-β and Mucin-2 (MUC2) ), which help increase the
mucosal barrier and allow for worms to be expelled (Fallon et al., 2006; Herbert et al.,
2009). Other cytokines, such as IL-22, have been described as mediating goblet cell
hyperplasia and inducing higher mucin production, which also aids in worm expulsion
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(Hasnain et al., 2010; Turner et al., 2013). None of these mechanisms have been studied in
relation to cyathostomin infection in horses.
The aim of this study was to evaluate gene expression of selected cytokines
and goblet cell-associated components following anthelmintic treatment with larvicidal
doses of fenbendazole and moxidectin in ponies naturally infected with cyathostomin
parasites. This study evaluated two post treatment time intervals (2 and 5 weeks) with
emphasis on the role of goblet cells and their potential involvement with worm expulsion.
An additional aim was to further evaluate the local and systemic pro- and antiinflammatory gene expression to the larvae and to treatment.
3.3

Materials and methods
3.3.1 Study design
This study was conducted under the approval of the University of Kentucky’s

Institutional Animal Care and Use Committee, protocol 2015-2092. Power calculation was
performed with G*Power analysis, version 3.1.5 (Heinrich-Heine-University Düsseldorf,
Düsseldorf, Germany). For comparison at two time points, a minimum detectable effect
size of 0.65, with α=0.05 and β=0.80 occurred with a group size of six. For overall
determination of treatment efficacy using a group of 12 yielded a minimum detectable
effect size of 0.54, with α=0.05 and β=0.80. Briefly, thirty-six mix-breed ponies, ranging
from 2-4 years of age with naturally acquired cyathostomin infection and allocated into
three treatment groups: fenbendazole treated (10 mg/kg orally for 5 consecutive days
(Panacur PowerPak, Merck Animal Health, Madison, NJ, USA)), moxidectin treated (0.4
mg/kg once orally (Quest, Zoetis, Kalamazoo, MI, USA)), and untreated control.
Allocation into blocks was established on decreasing magnitude of fecal egg counts
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(completed with Mini-FLOTAC (Cringoli et al., 2017b), detection limit of 5 eggs per gram)
and age. From each block, ponies were randomly allotted into each of the three treatment
groups, allowing for 12 ponies into each treatment group. Ponies were kept on pasture from
September through October 2015 and were euthanized at 2 and 5 WPT All study personnel
were blinded to treatment information and group allocation throughout the study.
Ponies were weighed on a certified livestock scale and individual doses of larvicidal
anthelmintic were prepared based off treatment group assignment and weight on Day -1.
Ponies receiving fenbendazole were treated once daily on Days 0-4, and the ponies
receiving moxidectin treatment were treated once on Day 4. At two weeks post treatment
(Days 18 and 19) six ponies from each treatment group (three each day) were randomly
selected for euthanasia and necropsy. The remaining 18 ponies remained on pasture and
were then euthanized and necropsied at 5 WPT (Days 35 and 36). Worm burdens and
enumerations, anthelmintic efficacy and evaluation of histopathologic reaction data have
previously been reported from this study (Bellaw et al., 2018; Steuer et al., 2018).
3.3.2 Sample collection
Weekly blood samples, starting at Day -7, were collected from all ponies until
euthanasia and placed into Tempus blood RNA tubes (Applied Biosystems, Foster City,
CA, USA) per the manufacturer’s instructions. The filled tubes were vigorously shaken for
15-30 seconds and incubated at room temperature for 24 hours. The blood samples were
then placed at -20C until further processing.
As part of the necropsy procedure, tissue samples measuring approximately
10x10mm were collected at necropsy from the CEC, VC, and DC. Tissue samples were
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placed directly into RNALater (Life technologies, Grand Island, NY, USA), and left at
room temperature for 24 hours. Then, all samples were refrigerated at 4C until further
processing.
3.3.3 Cytokine and gene expression
3.3.3.1 Blood RNA extraction and reverse transcription
Total RNA was isolated from whole blood tempus tube samples as described by
Page et al. Briefly, Samples were placed into 50mL tubes and washed with 3mL 1xPBS
and centrifuged at 300g for 10 minutes. 600µl of Viral Lysis buffer (Invitrogen, Carlsbad,
CA, USA) were added and to each sample and vortexed to suspend the pellet. RNA was
extracted with iPrep Total RNA Kit (Invitrogen) and the iPrep Purification Instrument
(Invitrogen). Samples were stored at -20°C until further use (Page et al., 2017).
Reverse transcription of the samples was carried out similarly to Nielsen et al 2015.
Briefly, RNA was quantified with a Biotek Epoch Biophotometer (Biotek, Winooski, VT,
USA). Reverse transcription reactions were carried out in an Applied Biosystems Veriti 96
well Thermal Cycler (Applied Biosystems, Foster City, CA, USA), using Promega
reagents (Promega, Madison, WI, USA). The cDNA was then diluted with an equivalent
volume of RNase-free water (80µL; Qiagen, Hilder, Germany). Samples were stored at 20°C until further use.
3.3.3.2 Tissue RNA extraction and reverse transcription
One hundred mg of the intestinal mucosa from the intestinal tissue samples were
used for RNA extraction. Samples were processed similarly to Liu et al. , with the following
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difference: Trizol (Invitrogen) was used in this process instead of RNA-STAT60 (Liu et
al., 2012). Reverse transcription was carried out as in 2.3.1, with the following exception:
41.5µl of tissue RNA was used for all tissue reactions to improve potentially low RNA
yields due to protein interference in spectrophotometer readings. cDNA samples were
stored at -20°C until further use.
3.3.3.3 Quantitative real time polymerase chain reaction
Gene expression was evaluated through quantitative RT-PCR assay (Breathnach et
al., 2006; M. K. Nielsen et al., 2015) for all blood and tissue samples. Equine specific
TaqMan intron spanning primers and probes (Thermo-Fisher Scientific, Carlsbad, CA,
USA) were used for this study. β-glucuronidase (β-GUS, Ec03470630_m1), IL-4
(Ec03468790_m1),

IL-5

(Ec03468691_m1),

IL-6

(Ec03468678_m1),

IL-10

(Ec03468647_m1),

IL-13

(Ec03470543_m1),

IL-17A

(Ec03470096_m1),

IFN-γ

(Ec03468606_m1), and TNF-α (Ec03467871_m1) were commercially available through
Thermo-Fisher Scientific and used in this study. Custom TaqMan® gene expression assays
were developed through Thermo-Fisher Scientific for IL-22 (AR9HJZX), MUC 2
(ARRWFPW), and RELM-β (AP47XR4). β-GUS was used as a housekeeping gene
(Breathnach et al., 2006).
Each reaction contained 5µl of Sensimix II probe kit master-mix (Bioline, London,
UK), 0.5µl of 20x TaqMan assay for primers and probes of interest (assays-by-design,
Applied Biosystems), and 4.5µl of diluted cDNA. Duplicate wells were prepared for each
sample and gene. Applied Biosystems 7900HT Fast-RT-PCR system was used to assess
gene expression. Incubation was the same as Nielsen et al 2015. LinRegPCR was used to
adjust qRT-PCR efficiencies (Ramakers et al., 2003). qRT-PCR data were normalized to
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the housekeeping gene (β-GUS), and analyzed using the 2-∆∆CT method (Livak and
Schmittgen, 2001).
3.3.4 Statistical analysis
Statistical analyses were carried out using SAS 9.4 (SAS Institute, Cary, NC, USA).
Mixed linear models were constructed for evaluating the effect of treatment group and days
post treatment on gene expression. The ‘mixed procedure’ was used and ‘horse ID’ kept as
a random effect. ‘Group’, ‘day’, and ‘organ’ were kept as class variables. Models were
built to analyze each cytokine, and organ was kept as a covariate. The traditional forward
and backward elimination of variables was used to evaluate the influence of all parameters.
Variables with P-values of 0.2 or below remained in the model and the interaction between
group and day was evaluated in all analyses (Kee and Koval, 1997). Log transformation of
variables was used, when appropriate, to achieve normal distribution. A ‘least square
means’ analysis was used for a Tukey’s pairwise comparison. A significance level of
α=0.05 was used for data interpretation. Figures and linear pairwise correlations were
conducted through JMP Pro 14 (SAS Institute, Cary, NC, USA), and a Pearson correlation
coefficient obtained. For the correlations, luminal and mucosal worm counts and stages,
goblet cell hyperplasia scores and associated gene expression, and all inflammatory
cytokine expression were used as variables.
3.4

Results
3.4.1 Goblet cell-associated, and anti-inflammatory cytokine gene expression
3.4.1.1 Gene expression in the intestinal tissue
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Differences were noted among the groups and timepoints for gene expression of IL-22,M
UC2, IL-10, and RELM- β (Figure 3-1). MUC2 gene expression was greater at 2 WPT
compared to the 5 WPT time point in all groups (Figure 3-2, p=0.0011), and greater in
the control group compared to the two treatment groups (p=0.0337, 0.0367) at 2 WPT. In
the moxidectin group, MUC2 was also elevated in at 2 WPT compared to 5 WPT (Figure
3-2, p=0.0033), which was noted neither in the fenbendazole treated nor control groups.
The anti-inflammatory IL-10 gene expression was elevated at 2 WPT compared to 5
WPT (Figure 3-1, p <0.0001). Tissue RELM-β gene expression was elevated at 2 WPT
compared to 5 WPT across groups (Figure 3-2, p=0.0361).
Differential gene expression of these genes occurred not only between
treatment groups and timepoints, but between the three intestinal organs as well.
IL-10 gene expression of the DC in the fenbendazole group was elevated compared to all
organs and time periods, whereas the control CEC expressed higher levels of IL-10 than
the CEC of both treatment groups (p<0.0001 and 0.0009, respectively). Additionally, the
CEC and DC of the fenbendazole group expressed higher levels of IL-10 than the CEC
and DC in the moxidectin group (p<0.05). Independent of treatment group, the CEC and
DC expressed higher levels of IL-10 than the VC (p=0.0095 and 0.0033, respectively),
and gene expression of IL-13 was higher in the DC compared to both the CEC and VC
(p<0.0032). IL-22 gene expression was also elevated in the DC compared to the VC
(p=0.0181), and MUC2 gene expression was lower in the CEC compared to the DC and
VC (Figure 3-3, p=0.0337 and 0.0367, respectively). Finally, RELM-β gene expression
was elevated in the DC compared to CEC and VC (Figure 3, p=0.0074 and 0.0182,
respectively).
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Figure 3-1. Box-whisker plots of relative quantities of the expression of interleukins
IL-10, IL-13, and IL-22 in intestinal tissues at two and five weeks post treatment.
Upper and lower bounds of the boxes represent the upper and lower quartiles,
respectively. Letters indicate significant differences between groups (p<0.05).
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Figure 3-2. Box-whisker plots of relative quantities of the expression of goblet cellassociated genes MUC2 (a) and RELM-β (b) in large intestinal tissues at two and
five weeks post treatment in the three different treatment groups (Control,
Fenbendazole, and Moxidectin). Upper and lower bounds of the boxes represent the
upper and lower quartiles, respectively. Letters indicate significant differences
between groups (p<0.05).
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Figure 3-3. Box-whisker plots of relative quantities of the expression and goblet cellassociated gene MUC2 in the tissues by treatment groups (Control, Fenbendazole
and Moxidectin) and intestinal organs; Cecum (CEC), Dorsal Colon (DC), and
Ventral Colon (VC). Upper and lower bounds of the boxes represent the upper and
lower quartiles, respectively. Letters indicate significant differences between groups
(p<0.05).
3.4.1.2 Gene expression in the systemic circulation
There were no differences in the circulating IL-10 and IL-13 gene expression
between the treatment groups and timepoints (p>0.05,Figure 3-2). IL-22, MUC2, and
RELM-β gene expression in circulation were elevated at prior to 3 WPT, where then
relative gene expression decreased across all groups, regardless of treatment (Figure 6-3,
p<0.0421).
3.4.2 Pro-inflammatory cytokine gene expression
3.4.2.1 Gene expression in the intestinal tissue
At 2 WPT, IL-4 gene expression of the control group was elevated compared to the
fenbendazole group (Figure 3-5, p=0.0027). IL-5 gene expression followed similar
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patterns, with the control group exhibiting higher gene expression than both treatment
groups (Figure 5, p<0.0237). Overall, there was higher gene expression of TNF-α in the
fenbendazole treated group than the moxidectin treated group (Figure 3-4, p<0.0352). At
2 WPT, the fenbendazole treated group also expressed higher levels of IFN-γ when
compared to the moxidectin treated group (Figure 4, p=0.0387). Regardless of treatment
group, IL-5, IL-6, and IFN-γ gene expression were elevated at 2 WPT compared to 5 WPT
(Figure 3-4, Figure 3-5, p=0.0113 and 0.0042, respectively). In the CEC, the control group
exhibited higher IFN-γ gene expression at 2 WPT compared to both treatment groups
(p<0.0078).
Regardless of time, the control CEC IL-4 gene expression was elevated compared
to all other organs of all groups (p<0.001). IL-5 gene expression followed similar patterns
with higher gene expression in the control CEC at 2 WPT compared to all other organs and
time points (p<0.0445). At 2 WPT, IL-5 gene expression was elevated in the fenbendazole
DC compared to moxidectin DC, and overall, IL-5 gene expression was higher in the
control DC compared to moxidectin DC (p<0.0389). Finally, in the VC, TNF-α was
expressed in higher levels in the fenbendazole-treated group compared to both the control
and moxidectin-treated groups (p<0.0073).
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Figure 3-4. Box-whisker plots of the relative quantities of the pro-inflammatory
cytokines IFN-γ (a) and TNF-α (b) in the intestinal tissues at two and five weeks post
treatment in the three treatment groups (Control, Fenbendazole, and Moxidectin).
Upper and lower bounds of the boxes represent the upper and lower quartiles,
respectively. Letters indicate significant differences between groups (p<0.05).
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Figure 3-5. Box-whisker plots of the relative quantities of the pro-inflammatory
cytokines IL-4, IL-5, and IL-6 in the intestinal tissues at two and five weeks post
treatment in the three treatment groups (Control, Fenbendazole, and Moxidectin).
Upper and lower bounds of the boxes represent the upper and lower quartiles,
respectively. Letters indicate significant differences between groups (p<0.05).

3.4.2.2 Gene expression in systemic circulation
There were no differences in the circulating IL-10 and IL-13 gene expression
between the treatment groups and timepoints (p>0.05, Figure 6-4). IL-22, MUC2, and
RELM-β gene expression in circulation were elevated at prior to 3 WPT, where then
relative gene expression decreased across all groups, regardless of treatment (Figure 6-3,
p<0.0421).
3.4.3 Correlation of gene expression, goblet cell hyperplasia, and worm burdens
3.4.3.1 Correlations in the intestinal tissue
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There was negative correlation between worm burdens of the large intestinal organs
and IL-4, and negative correlations between worm burdens and IL-22 (Table 3-1, p<0.05).
Interestingly, goblet cell hyperplasia had a negative correlation with IFN-γ and IL-10.
Luminal worm counts also negatively correlated to MUC2 and RELM-β (Table 3-1,
p<0.05). Some of the evaluated genes also exhibited linear relationships with other genes,
(Table 6-4). IL-22, MUC2 and RELM-β were strongly correlated with each other in tissue
(Table 6-4, p<0.05).
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Table 3-1. Pairwise Pearson product-moment correlations to assess linear
relationships of gene expression within the tissues and worm burdens and goblet cell
scores. The r values are presented here. Those in BOLD are statistically significant
with p<0.05.
GCH

IFN-γ

IL-10

IL-13

IL-22

IL-4

IL-5

IL-6

MUC2

RELM- β

TNF- α

EN
total
CEC

0.2587

-0.0256

-0.0414

0.1168

-0.1645

-0.1919

-0.0076

0.3003

-0.1619

-0.1107

0.6825

EN
Total
VC

0.0313

-0.0445

-0.1132

-0.2705

-0.2096

-0.2945

-0.0364

0.2618

-0.2173

-0.1568

0.6106

EN
Total
DC

0.0997

-0.1746

-0.1584

-0.0929

-0.269

-0.4238

0.1509

0.1501

-0.2543

-0.2306

-0.1137

EN
Total
All
Organ
s

0.1597

-0.0506

-0.0874

-0.0597

-0.2075

-0.2742

-0.0043

0.2855

-0.2077

-0.1512

0.6423

EL3
CEC

0.3129

-0.01

-0.0288

0.2455

-0.1261

-0.1348

0.0033

0.4152

-0.1216

-0.0847

0.5756

EL3
VC

0.0107

0.0266

-0.1124

-0.2326

-0.2629

-0.2408

-0.04

0.3921

-0.252

-0.1845

0.5735

EL3
DC

0.1621

-0.0092

-0.2145

0.166

-0.2817

-0.3507

0.1426

0.5369

-0.2786

-0.2509

-0.1145

EL3
Total

0.2095

0.0043

-0.0854

0.0512

-0.2151

-0.2187

0.0034

0.4332

-0.2074

-0.1549

0.5542

LL3/L
4
CEC

0.0864

-0.0593

-0.0621

-0.1824

-0.2194

-0.2848

-0.0311

-0.006

-0.2215

-0.1481

0.7614

LL3/L
4 VC

0.046

-0.1236

-0.0794

-0.352

-0.1016

-0.2788

-0.0203

-0.0066

-0.1199

-0.0834

0.6526

LL3/l
4 DC

-0.0697

-0.3312

0.0075

-0.174

-0.0846

-0.2945

0.0689

-0.2167

-0.0565

-0.0545

-0.0666

LL3/l
4
Total

0.0552

-0.1396

-0.0711

-0.2777

-0.1608

-0.3139

-0.0176

-0.0418

-0.169

-0.1167

0.7201

Lumi
nal
Worm
s per
organ

0.1233

0.0293

-0.2765

-0.0671

-0.1694

-0.3446

0.1657

0.1293

-0.1678

-0.2137

0.5509

Lumi
nal
Worm
Total

0.1994

-0.0361

-0.341

-0.0169

-0.1923

-0.2487

-0.0126

0.0544

-0.2358

-0.2261

-0.0819

-0.3668

-0.2764

-0.1695

-0.2155

-0.0698

-0.126

-0.2406

-0.2467

-0.1719

-0.4904

GCH
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3.4.3.2 Correlations in systemic circulation
IL-13 and IL-6 positively correlated to both luminal and encysted worm counts,
whereas IL-22, MUC2, and RELM-β only had positive correlation to encysted worm
burdens (Table 3-2, p<0.05). Many of the cytokines exhibited linear correlations in the
blood as well, including MUC2 and RELM-β (Table 6-3).
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Table 3-2. Pairwise Pearson product-moment correlations to assess linear
relationships of gene expression within the blood and total worm counts and GCH
scores. The r values are presented here. Those in BOLD are statistically significant
with p<0.05. Abbreviations for table above: EL3, early third larval stage; LL3, late
third larval stage; L4, fourth larval stage; GCH, Goblet Cell Hyperplasia average
score; IL, Interleukin; MUC2, Mucin 2, RELM- β, Resistin-Like Molecule Beta;
TNF-α, Tumor Necrosis Factor- α.

IL-17A
IL-22
IL-4
IL-5
IL-6
MUC2
RELM-β
TNF-α

0.0473

IL-13

0.2345

0.0675

IL-10

0.2132

0.2198

0.0488

0.059

0.2463

0.204

-0.0402

0.0679

0.2443

-0.0765

0.1673

-0.0292

0.1309

0.2238

0.1701

-0.1301

0.1525

0.1066

0.2335

0.2035

0.1362

0.0602

0.2321

-0.104

-0.0618

0.199

0.0391

-0.0084

0.1688

0.2393

0.0564

-0.0408

0.1606

0.2156

-0.0399

0.1911

-0.1506

0.0945

-0.0193

EL3
Total

0.0533

0.0766

-0.092

0.2355

LL3/L4
Total

-0.0841

0.252

-0.0047

GCH

0.0301

Encysted
Total

Luminal
Worm
Total
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3.5

Discussion
This is the first study to evaluate reactions to equine cyathostomin infection with a

specific focus on goblet cells and their function, and the first to evaluate gene expression
of IL-13, IL-17A, IL-22, RELM-β, and MUC2 following larvicidal treatment. The study
has provided new insight into host-parasite interactions with cyathostomin infections and
suggested mechanisms involved with spontaneous worm expulsion.
The study population was uniquely suited for this study. These ponies were born
on the research farm and had been kept together on the same pastures since then, and they
had not received anthelmintic treatments since the year before. The age range (2-4 years)
was particularly appropriate for this study, as this is when encysted cyathostomin burdens
are reported to be at their highest (Melanie R Chapman et al., 2003). Furthermore, larval
cyathostominosis is reported to occur at a higher frequency in horses younger than 5 years
of age (Reid et al., 1995). Finally, it is important to study these aspects in naturally infected
horses as no experimental infection protocol can appropriately mimic daily ingestion of
infective cyathostomin larvae and their species composition. Concerning the role of goblet
cells and their function, it is interesting to note the higher gene expression of MUC2 and
RELM-β in the tissues across all groups at the 2 WPT time interval compared to 5 WPT,
while IL-13 exhibited the opposite effects. In our previous histopathological study, we
reported an increase in goblet cell hyperplasia at 5 WPT compared to 2 WPT, which
suggests the increase in IL-13 reported herein could be associated with this process, as
reported in other species (Steuer et al., 2018; Turner et al., 2013). This and the decreased
gene expression of MUC2 and RELM-β coincided with the previously reported decreased
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mucosal worm burdens at 5 WPT (Hasnain et al., 2013b). While typically associated with
worm expulsion and goblet cell proliferation, the higher gene expression of IL-10 reported
herein coincided with the previously reported decreased goblet cell scores (summarized in
Supplemental Figure 3-5) and higher counts of encysted larvae in the mucosal tissues
(Bellaw et al., 2018; Steuer et al., 2018). This suggests that IL-10 negatively correlates
with goblet cell hyperplasia in these horses; however, it is likely not a linear relationship
(Table 1). There may also be a direct correlation with IL-22, IL-10, and the goblet cell
products MUC2 and RELM-β (Supplemental Table 3-2). This suggests a potential negative
feedback loop on goblet cell hyperplasia with IL-13 and positive feedback loops with IL22 and IL-10. Here, IL-22 and IL-10 may result in a decrease in goblet cells (Table 3-1),
and IL-13 may be associated with an increase in cyathostomin infections; however, this
needs further investigation to unravel the exact role that cyathostomins play in the potential
immune modulation. It would also be interesting to further investigate the course of events
between 2 and 5 WPT to follow the progression of expression of these genes to better
understand the exact mechanisms occurring in the tissues. In rodent models infected with
Trichuris muris, IL-22 is known to mediate goblet cell hyperplasia and induce worm
expulsion, as with other worm models in rodents and worm expulsion (Inclan-Rico and
Siracusa, 2018; Turner et al., 2013). The decrease in gene expression of IL-22, MUC2 and
RELM-β at 2 WPT in whole blood corresponded with our observations in the mucosal
tissue samples, indicating a tissue spill-over of cells expressing these cytokines and genes
into the blood circulation, as previously suggested (Nielsen et al., 2015).
In regard to the pro-inflammatory cytokines expressed in the intestinal tissues, we
generally found the same pattern as the other cytokines and genes associated with goblet
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cell hyperplasia, with higher gene expression at 2 WPT compared to the 5 WPT time point.
However, there were additional differences associated with anthelmintic treatment. In
contrast to fenbendazole, moxidectin-treatment appeared to suppress IL-5 and TNF-α at 2
WPT, when compared to the control. The lack of a similar fenbendazole effect could be
due to the reduced anthelmintic efficacy for this treatment in the study, and thus a reflection
of the worm burden rather than treatment (Bellaw et al., 2018). This is supported by the
elevated gene expression of IFN-γ and TNF-α in the control CEC and VC, respectively.
Overall, gene expression of IL-5 at 2 WPT was greater in the control group than the two
treatment groups, and greater in the fenbendazole-treated group compared to the
moxidectin group, suggesting that moxidectin’s higher larvicidal and overall treatment
efficacy caused suppression of IL-5 by decreasing worm burdens. Thus, encysted larval
burdens may play a significant role in IL-5 production within these mucosal tissues.
Nematode mediation of IL-5 has previously been reported in rodent models infected with
N. brasiliensis (Fallon et al., 2006).
Finally, this study demonstrated that the intestinal organs had significantly different
levels of gene expressions. This may reflect differences in resident worm burdens between
these organs, or it could be due to different immunological reactions at the organ level.
Further unravelling these mechanisms remains a future area of research, as this has not
been previously reported in studies and is a new area of interest in understanding not only
infections, but the disease process as well (Davidson et al., 2005, 2002). There was a
general trend for the DC to express higher levels of cytokines and goblet cell hyperplasiaassociated genes, which are generally associated with the lower cyathostomin worm
burdens found in the DC. In our previous work, we found that the VC had more goblet cell
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hyperplasia and higher mucosal larval counts, which is in agreement with the greater
MUC2 gene expression observed in the VC and reported herein (Bellaw et al., 2018; Steuer
et al., 2018).
It is important to consider the efficacy of both moxidectin and fenbendazole in this
study, which were 70.8% and 74.6% for encysted LL3s/L4s at 2 WPT and 73.8% and 50.4
% for encysted EL3s, respectively (Bellaw et al., 2018). These larvicidal efficacies were
not statistically different from each other, and neither exhibited a 100% larval reduction.
However, they both removed similar proportions of encysted larvae, but utilized different
modes of action. Despite this, there were limited differences between treatment groups,
including the untreated control. Nonetheless, it remains challenging to separate effects
associated with the drugs themselves from changes in larval numbers present within the
large intestine. The remaining larvae within the mucosa still maintain a potentially
significant antigenic potential, and while we compare against an untreated control group,
these remaining larvae may serve as a source of confounding in interpretation of the data.
However, as documented by our laboratory, none of the currently available anthelmintic
products labelled for larvicidal therapy can be expected to completely eliminate the
encysted burden, so this study is evaluating a realistic real-life scenario (Bellaw et al., 2018;
Reinemeyer et al., 2015). The data reported herein suggest that larvicidal treatment itself
may not have an effect long term (2-5 weeks); however, more work is needed evaluating
responses closer to the time of treatment allowing a better assessment of effects associated
with the resultant acute worm die-off.
In conclusion, this is the first study evaluating gene expression with particular focus
on goblet cells in equids naturally infected with cyathostomins during a five-week time
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period post larvicidal treatment. Herein, we have provided evidence of interaction between
parasites, anthelmintic treatment, and the equine immune system. This study illustrated that
goblet cells likely play an important role in the host response to mucosal cyathostomin
burden and appears involved with the worm expulsion observed between the 2 and 5 WPT
time intervals. Furthermore, we have illustrated that the CEC, VC, and DC respond
differently to these stimuli and these aspects represent compelling avenues of future
research aiming at improving our understanding of host-parasite interactions with
cyathostomin parasites.
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CHAPTER 4. HISTOPATHOLOGICAL ANALYSES OF LARVICIDAL VERSUS NONLARVICIDAL
TREATMENT: IS KILLING PARASITES REALLY BETTER?
4.1

Introduction
Cyathostomins are inevitable parasites in horses with infection rates reaching

between 90-100% of grazing horse herds (Chapman et al., 2003; Monahan et al., 1998;
Reinemeyer et al., 1986; Verkaaik, 2016). The collective cyathostomins includes 8 genera
of 40 species infecting domestic horses (Lichtenfels et al., 2008). The life cycle is
considered unique and complex among strongylid parasites of animals, where the encysted
larvae undergo hypobiosis at the early third larval stage for up to two to three years (EL3)
(Eysker and Mirck, 1984; Smith, 1976a), then proceed through development to the late
third stage and fourth stage larvae (LL3/L4, respectively). Hundreds of thousands of larvae
can accumulate over time, and this accumulation is believed to be driven by the host
reaction to the parasites (Chapman et al., 2003). Larval accumulation appears to be
associated with seasons, with notably higher mucosal counts occurring after the grazing
season, and when pasture conditions will be unfavorable for parasite development and
maturation (Leathwick et al., 2016; Nielsen et al., 2018b, 2007).
Since the 1970s, the processes of encystment and excystment have been associated
with a local inflammatory reaction surrounding each individual larva (Ogbourne, 1978). A
pronounced typhlocolitis reaction and disease has been associated with mass excystment
of the L4s from the tissue, a disease complex known as larval cyathostominosis (Love et
al., 1999). While the disease complex is well described, the local and systemic
inflammatory and immunological mechanisms of disease and infection are still poorly
understood.

There are currently three drug classes available for use against the cyathostomins:
benzimidazoles, pyrantel salts, and the macrocyclic lactones. Cyathostomins have
widespread resistance to the benzimidazoles and pyrantel salts; however, there is very little
evidence of resistance to the macrocyclic lactones (MLs) at this time (Kaplan et al., 2004;
Lester et al., 2013; Peregrine et al., 2014). All MLs are broad spectrum anthelmintics;
however, only moxidectin gel administered at 0.4 mg/kg once orally targets the encysted
stages, specifically it is only labeled in the United States for the LL3/L4s. Ivermectin at the
labeled 0.2 mg/kg once orally dose is not labeled to target the encysted stages, and most
studies support this finding even with elevated doses (Klei et al., 1993).
When evaluating the local histopathological inflammatory response to treatment,
studies have compared the only two larvicidal regimens available, which are in different
drug classes: moxidectin as dosed above and fenbendazole (Nielsen et al., 2015; Steinbach
et al., 2006; Steuer et al., 2018). However, few significant differences were actually noted
between the studies, and the earlier studies had contradictory findings. One study suggested
that there was a significantly reduced local inflammatory response in ponies treated with
moxidectin compared to the larvicidal fenbendazole protocol (Steinbach et al., 2006).
Inversely, In 2015, Nielsen et al. elucidated subtle decreased inflammatory reactions in the
fenbendazole treated group; however, this was suggested to be due to the decreased
efficacy of fenbendazole and therefore decreased efficacy of the treatment and lower
inflammatory reaction to dying larvae (Nielsen et al., 2015). In this same study, no
differences in systemic inflammatory responses were noted (Nielsen et al., 2015). In 2018,
we completed a similar study, with results reported in chapters 2 and 3 of this dissertation.
Briefly, we noted that there were no significant differences in the overall local and systemic
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inflammatory response to these to treatments that had similar larvicidal efficacies. The
most significant finding was the relationship between the worm burdens, and goblet cell
hyperplasia (GCH) and the related genes, thus potentially implicating GCH in worm
turnover, which has been described in other host-parasite interactions (Hasnain et al.,
2013a, 2010; Herbert et al., 2009).
Studies have not evaluated the local inflammatory response to the solely adulticidal
ivermectin, even though adulticidal therapy is implicated in larval cyathostominosis (Reid
et al., 1995). Previous studies that have evaluated the inflammatory reaction to ivermectin
compared it to oxibendazole, moxidectin and a few other products. These studies noted no
differences between the treatment groups; however, these studies noted intestinal
erythema, edema and ulceration to worm burdens themselves (Love, 1995; Monahan et al.,
1998, 1996). This is consistent with our previous findings (Steuer et al., 2018). The aims
with the present study were to collect further histopathological information on local
inflammatory responses to anthelmintic therapy and perform the first comparison of
histopathological reactions observed at the two different time intervals post anthelmintic
treatment between larvicidal and nonlarvicidal ML treatment in adult horses.
4.2

Materials and Methods

4.2.1 Study design
This study was performed under the University of Kentucky’s Institutional Animal
Care and Use Committee, protocol number 2018-3134. Power calculations for the group
sizes have previously been reported (Bellaw et al., 2018). Thirty-six horses with naturally
acquired cyathostomin infections, aged 2-5 years old, were kept on pasture from August92

October 2019. To allocate into groups, horses within a birth year were grouped by sex and
then ranked by decreasing magnitude of egg counts (Cringoli et al., 2017). Then horses
were blocked into groups of three and within each block randomly allocated into each
group. Finally, the horses were then randomly allocated into one of the two time intervals.
Each group contained a total of 12 horses, with 6 horses allocated to each of the two time
intervals. All study personnel were blinded to group allocations and treatments throughout
the study.
On day -10, each horse was weighed on a certified livestock scale, and feces taken
for group allocation, as defined above. Horses in the moxidectin group received 0.4mg/kg
orally (Quest Plus, Zoetis Inc., Parsippany, NJ, USA), and horses in the ivermectin group
received 0.2mg/kg ivermectin orally (Zimectrin Gold, Boehringer Ingelheim, Duluth, GA,
USA) on Day 0. The horses in the untreated control group did not receive any treatment.
Six horses from each group were euthanized on days 14 and 15 (2 weeks post
treatment). Three horses from each group were necropsied each day to ensure equal
numbers of horses from each group were necropsied simultaneously. The remaining 18
horses were kept on pasture until they were euthanized in the same manner as above, on
days 35 and 36 (5 weeks post treatment).
4.2.2 Mucosal worm enumeration
This method was previously reported (Bellaw et al., 2018). Briefly, 5 % mucosal
sections by weight were taken from each of the large intestinal organs. The mucosa and
submucosa were scraped off the surface and placed within 1:100 mixture of hydrochloric
acid to water, with 10mg pepsin added per liter. The tissue was then digested at 37ºC for 2
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hours. A 2% subsample was taken, washed, and stained with Lugol’s iodine solution and
evaluated for EL3 and LL3 larvae under a dissection scope. Larvae totals were estimated
by taking the number of larvae found and multiplying by a factor of 1000.
4.2.3 Tissue sample harvesting
At necropsy, tissue samples, approximately 2x2cm, were taken along a taenial
band, approximately 6cm apart, from grossly normal cecum (CEC), dorsal colon (DC), and
ventral colon (VC). Samples were placed in 10% buffered neutral formalin for 24h and
then stored in 70% ethanol at 4C until further processing.
4.2.4 Histology
All tissue samples were routinely processed and stained with Harris hematoxylin
and eosin. All samples were analyzed by light microscopy as previously described (Steuer
et al., 2018), and approximately 50mm in length of mucosa was examined. Briefly, larvae
were evaluated based off of size and morphologic characteristics to determine stage (L3 or
L4). Larvae were counted, and lesions surrounding the larvae, were evaluated for location
(colonic glands, mucosal epithelium, lamina propria, and submucosa), size, inflammatory
cell composition (neutrophils, eosinophils, macrophages, and lymphocytes) and severity of
inflammation and fibrosis. Scores were given based off of the following: 0=none, 1=1-5
cell layers, 2= 6-15 cell layers, and 3=>15 cell layers. Tissue sections were also evaluated
and scored for the presence of goblet cell hyperplasia, mucosal ulcerations, and submucosal
granulomas as previously described (Steuer et al., 2018).
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4.2.5 Immunohistochemistry
Immunohistochemistry (IHC) was used to characterize and semi-quantify the
products of the goblet cells. Tissue sections were immunohistochemically stained (Leica,
BOND-MAX Stainer, Leica Biosystems, Buffalo Grove, IN, USA) for Mucin 2 (antibody
PA5-79702, Invitrogen, Carlsbad, CA, USA), Mucin5AC (antibody PA5-83504,
Invitrogen, Carlsbad, CA, USA), and Resistin-Like Molecule Beta (antibody PA5-61896,
Invitrogen, Carlsbad, CA, USA). The number of immunohistochemically stained cells
were counted per 10 intact glands within a sample. Along with IHC staining, samples were
stained with PAS/Alcian Blue (Richard-AllenTM Scientific Alcian Blue/PAS Special
Stain Kit, Thermo ScientificTM, Waltham, MA, USA) per manufacturer’s instructions for
evaluation and enumeration of mucins within the goblet cells.
4.2.6 Statistical Analyses
Statistical analyses were carried out using SAS 9.4 (SAS Institute, Cary, NC, USA).
Mixed linear models were constructed for evaluating the effect of treatment group and days
post treatment on histopathological findings. The ‘glimmix procedure’ was used and ‘horse
ID,’ ‘Age,’ and ‘sex’ kept as a random effects. ‘Group’, ‘day’, and ‘organ’ were kept as
class variables. The traditional forward and backward elimination of variables was used to
evaluate the influence of all parameters. Variables with P-values of 0.2 or below remained
in the model and the interaction between group and day was evaluated in all analyses (Lee
and Koval, 1997). A ‘least square means’ analysis was used for a Tukey’s pairwise
comparison for categorical variables when p<0.05. A significance level of α=0.05 was used
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for data interpretation. Figures were developed in JMP Pro 14 (SAS Institute, Cary, NC,
USA.
4.3

Results
4.3.1 Worm burden
Mucosal worm burden and anthelmintic efficacy is described in Table 4-1. There

were no significant differences in mucosal larval burden between the groups. Significantly
lower EL3 and LL3 counts were observed in the VC compared to the CEC and DC;
however, the VC had higher encysted larval burden (p<0.001, Figure 4-1). Mucosal worm
burdens were highest at 2 WPT. This was supported within the histological evaluation of
the larval stages as well (p>0.05).
Table 4-1. Mucosal larval burdens in the treatment groups with mean, range and
efficacy provided.
Treatment Group

Interval

Mean

Range

Efficacy

2

26333

3000-63000

18.13

5

13333

3000-25000

8.05

2

62333

10000-85000

-93.78

5

33333

11000-90000

-129.89

2

32167

5000-83000

5

14500

2000-28000

2

16833

0-59000

60.39

5

19167

2000-52000

21.23

2

36500

10000-85000

14.11

5

29333

9000-57000

-20.5

2

42500

0-161000

EL3s
Moxidectin

Ivermectin

Control

LL3/L4s
Moxidectin

Ivermectin

Control
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5

24333

7000-47000

2

43167

3000-101000

42.18

5

32500

8000-62000

16.3

2

98833

18000-297000

-32.4

5

62667

34000-147000

-61.4

2

74667

7000-184000

5

38833

10000-71000

Total Mucosal Counts
Moxidectin

Ivermectin

Control

Table 4-2. (continued)
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Figure 4-1. Box and whisker plots of the worm counts from the organs. Different
letters denote significant differences between organs. Upper and lower bounds of the
boxes represent the upper and lower quartiles, respectively.

4.3.2 Inflammatory Cells
There were no significant differences between treatment groups, organs, or
timepoints in the present study (Figure 4-2). Neutrophil scores were associated with larval
stage; L4s were associated with higher scores than LL3s and EL3s (p=0.0040).
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Figure 4-2. Inflammatory scores presented by groups and weeks post treatment.
There were no significant differences noted between the groups or time intervals.
Upper and lower bounds of the boxes represent the upper and lower quartiles,
respectively.
4.3.3 Goblet Cells
Across all groups, GCH was elevated at 2 compared to 5 WPT (p=0.0029, Figure
4-3). GCH scores were lowest in moxidectin treated versus the ivermectin treated and
untreated controls (p<0.0001, Figure 4-3). Scores were positively associated with worm
burden, and highest in the VC compared to the DC and CEC, with the DC higher than the
CEC (p=0.0495). Alcian blue and PAS stained counts were positively associated with
GCH, and significantly followed similar trends with organs, WPT, and groups (p=0.0252),
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and the ratio between the stained cell counts positively associated with higher GCH scores
(p=0.0043).
MUC2 counts were highest in the VC, followed by the CEC and then the DC
(p<0.0367, Figure 4-4). MUC2 counts were also negatively associated with total organ
encysted larval counts (p<0.0001). MUC5AC was positively associated with GCH and
negatively associated with total encysted larval counts (p=0.0066). In the tissues,
MUC5AC expression was highest in the DC, compared to CEC and VC (p=0.0317, Figure
4-4). RELM-ß followed similar trends to MUC2 and MUC5AC; however, it was lowest in
the CEC (p=0.0032, Figure 4-4).

Figure 4-3. Goblet Cell Hyperplasia scores by group and weeks post treatment.
Different letters denote significant differences between timepoints. Upper and lower
bounds of the boxes represent the upper and lower quartiles, respectively.
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Figure 4-4. GCH and products scores differentiated by organ. Different letters
denote significant differences between organs. Upper and lower bounds of the boxes
represent the upper and lower quartiles, respectively. Abbreviations are cecum
(CEC), ventral colon (VC), and dorsal colon (DC).

4.4

Discussion
This study is the first to evaluate ivermectin in regard to the local histopathological

findings following treatment at two time points. Overall, there were no significant
differences in the pro-inflammatory cells present; however, we did note decreased GCH in
horses after receiving treatment, with lowest GCH scores occurring in the moxidectin
treated horses compared to ivermectin. This does indicate a difference in the two
treatments, with a stronger host response when more encysted larvae remain.
The most interesting finding of the present study was the association between GCH
and worm burdens. Higher GCH scores at 2 WPT were associated with the higher larval
burdens, and this is supported by studies in other species (Hasnain et al., 2010; Turner et
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al., 2013); however, this contradicts our previous findings, where mucosal worm counts
were inversely correlated with GCH scores (Steuer et al., 2018). Our present study more
accurately depicts a role in worm expulsion occurring over time. Findings in our previous
study led to the hypothesis that worm turnover was occurring regardless of treatment
(Steuer et al., 2018). This current study supported this hypothesis, as we observed the same
trend in mucosal counts and GCH was associated with these decreasing worm burdens. At
present, we are unable to evaluate the role of luminal counts in this process, but GCH
directly correlated with luminal worm burdens in the previous study (Steuer et al., 2018).
It is speculated that this is the case here as well. This is directly supported by the fact that
there were significant differences between the treatment groups in regard to GCH, with the
moxidectin group, which had the lowest worm burdens, having lower scores than the
ivermectin group, which, in turn had lower scores than the control group. This signifies
that with less worms, there is less of a mucosal inflammatory reaction to worms and
decreased worm expulsion; however, luminal counts need to be assessed to support this
claim.
This is the first study to identify MUC5AC in the intestinal tissue of horses. It was
reported in low numbers of stained goblet cells and associated with GCH and worm counts.
This indicates a potential active component in worm expulsion, which has been previously
reported only in other species (Hasnain et al., 2011, 2010; Ma et al., 2018; Rousseau et al.,
2011). This is neither a common, nor typical mucus produced within the intestines, and is
only previously reported in the airways of horses; however, it is also found in the gastric
glands of the horses, which was used as a positive control in this study. MUC2 and RELMß stained cells followed similar patterns to MUC5AC, and this indicates their critical role
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in worm expulsion, as depicted in other host and parasite species (Chen et al., 2018;
Hasnain et al., 2013a, 2010; Herbert et al., 2009; Ma et al., 2018). This was previously
reported in chapter 3 of this dissertation, where MUC2 gene expression significantly
correlated with GCH and worm burdens.
One further component was evaluating acidic versus neutral mucins. This study
aimed at evaluating neutral pH mucins versus acidic pH mucins, to see if there was a
difference in the types of mucins potentially involved. The presence of both acidic (PAS
stained mucins) and neutral mucins (Alcian blue stained mucins) increased with GCH and
worm counts; however, it was interesting to note is that, with higher GCH and worm
burdens, the ratio changed as well, with an increase in acidic mucins being produced. This
may suggest that in higher worm burdens are associated with a more acidic environment.
This may be the host response to incite turnover of the worms into the lumen and out of
the host.
In regards to encysted larval counts, efficacies were similar to those that were
previously reported (Bellaw et al., 2018; Eysker et al., 1997, 1992; Love, 1995; Xiao et al.,
1994). The overall larval counts were not significantly different between the treatment
groups, which may help explain the lack of significant differences between treatment
groups in regard to the inflammatory response. This is consistent with previous studies as
well (Nielsen et al., 2015; Steinbach et al., 2006; Steuer et al., 2018). Inflammatory cell
populations were not significantly different among groups. This is again consistent with
previous reports (Nielsen et al., 2015; Steinbach et al., 2006; Steuer et al., 2018). The focal
inflammatory reaction surrounding the encysted larvae did not appear to be significantly
impacted by treatment, which is what we have previously reported (Steuer et al., 2018).
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However, as developing and later stage larvae had greater inflammatory cell populations,
this indicates the potential for immune modulation by the parasites, or parasites undergoing
immune modulation. In fact, the inflammatory reaction, regardless of treatment, is most
likely driven by the host-parasite interaction and larval stages, and this requires further
investigations.
Finally, this study once again demonstrated that the three large intestinal organs
may have a different response to worm burdens, as noted in Chapters 2 and 3 of this
dissertation. This raises the question into why we see differences in worm burdens and in
the inflammatory responses between the organs, and what this may indicate in intestinal
disease. In general, during cyathostomin infections, the large intestine is regarded as a
whole; however, this study, along with our previous study, suggests that the VC may have
less of a proinflammatory reaction pattern compared to the DC, and the CEC may have
high turnover of larvae overall, as demonstrated here and previously (Steuer et al., 2018).
It is possible that identifying the exact mechanisms behind this may shed light on managing
worm burdens, diagnosis, and treatment.
In conclusion, this study found no significant differences in inflammatory cell
populations following larvicidal versus nonlarvicidal treatment and untreated horses;
however, GCH and its role in response to treatment is necessary to consider in future
studies. Further investigations into the role of goblet cell hyperplasia and worm turnover
need to be considered in the future to understand the reactions to anthelmintic treatment
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CHAPTER 5. CYTOKINE AND GOBLET CELL GENE EXPRESSION FOLLOWING TREATMENT
5.1

Introduction
Horses are host to cyathostomins, a dynamic groups of parasites, with over 8 genera

and 40 species in domesticated horses alone (Lichtenfels et al., 2008). The somewhat
complex direct lifecycle involves up to several hundred thousand larvae infecting the host’s
cecum (CEC), ventral colon (VC), and dorsal colon (DC). Larvae penetrate as early third
stage larvae (EL3s) and encyst, where they may undergo hypobiosis for up to 2 years and/or
proceed through development to the late third and fourth stage encysted larvae (LL3s/L4s,
respectively) (Eysker and Mirck, 1984; Ogbourne, 1975). This hypobiosis is believed to
be driven by the host response to the parasites; however, the mechanism is poorly
understood (Chapman et al., 2003). Larger accumulations are associated with age and
seasons, with noticeably higher counts occurring in horses 2-5 years of age and the highest
counts occurring after the grazing season (Ogbourne, 1975). There are noted inflammatory
responses surrounding each individual larvae; however, disease is characterized when large
numbers of L4 excyst en masse, producing a generalized typhlocolitis, a condition also
known as larval cyathostominosis (Love et al., 1999). Few studies have evaluated the
mechanisms behind the immunological and inflammatory processes in diseased as well as
clinically normal horses. Only one study thus far has evaluated cytokine gene expression
in the large intestinal tissues of horses with and without large intestinal disease, including
three cases with larval cyathostominosis (Davidson et al., 2002). They found that Tumor
Necrosis Factor (TNF)-α was expressed in horses with inflammatory bowel disease;
however, there were no significant differences occurring between the groups with and
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without large intestinal disease, including those with encysted cyathostomins present
(Davidson et al., 2002). Another study evaluated local tissue gene expression levels of
Interleukin (IL)-4, IL-5, IL-10, Interferon (IFN)-γ, in large intestinal tissues with and
without encysted larvae present (Davidson et al., 2005). Tissues with encysted
cyathostomins present expressed higher levels of IL-4, IL-5, and IL-10 than those without,
whereas expression of IFN-γ did not differ between the two groups (Davidson et al., 2005).
When evaluating the local inflammatory response to treatment, studies have
targeted comparing the only two larvicidal regimens available: moxidectin at 0.4mg/kg
once orally as dosed above and fenbendazole at 10 mg/kg orally for five days (Nielsen et
al., 2015; Steinbach et al., 2006; Steuer et al., 2018). These studies were based on
evaluating the differences in responses to two different drug classes; however, few
significant differences were noted between the studies, and the earlier studies had
contradictory findings. One study suggested that there was a significantly reduced local
inflammatory response in ponies treated with moxidectin compared to the larvicidal
fenbendazole protocol based on qualitative histopathological findings (Steinbach et al.,
2006). Inversely, we have evaluated the local and systemic inflammatory response to
moxidectin and fenbendazole in two different studies. In 2015, we found subtle decreased
inflammatory reactions in the fenbendazole treated ponies compared to moxidectin;
however, this was attributed to the decreased efficacy of fenbendazole, and not to actual
differences between the two anthelmintics themselves (Nielsen et al., 2015). In 2018, we
completed the study reported in Chapters 2 and 3 of this dissertation. Briefly, we noted that
there were no significant differences in the overall local and systemic inflammatory
response to these to treatments that had similar efficacies. The most significant finding was
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the relationship between the worm burdens, and goblet cell hyperplasia (GCH) and the
related genes. This potentially implicated GCH in worm turnover, similar to what has been
described in other host-parasite interactions (Hasnain et al., 2013a, 2010; Herbert et al.,
2009).
Of the three currently available drug classes, only the macrocyclic lactones (MLs)
do not have widespread resistance reported in cyathostomin populations (Kaplan et al.,
2004; Lester et al., 2013; Peregrine et al., 2014). While both MLs are labeled as broad
spectrum, only moxidectin gel administered at 0.4 mg/kg once orally targets the encysted
stages. Specifically, in the United States it is labeled for the LL3/L4s, whereas in the rest
of the world it has a label claim for all stages. Ivermectin at the labeled 0.2 mg/kg once
orally dose is not labeled to target the encysted stages, and most studies support this finding
even with elevated doses (Klei et al., 1993); however, few studies have demonstrated some
efficacy against the encysted stages (Eysker et al., 1992; Love, 1995).
Studies have not thoroughly evaluated the local inflammatory response to solely
adulticidal ivermectin, even though adulticidal therapy is implicated in the disease process
behind larval cyathostominosis (Reid et al., 1995). Previous studies that have evaluated the
inflammatory reaction to ivermectin and compared to oxibendazole, moxidectin and other
products noted intestinal erythema, edema and ulceration to worm burdens, but no
differences between treatments (Love, 1995; Monahan et al., 1998, 1996). These studies
have not quantified the inflammatory reaction, nor evaluated cytokine and gene expression
within the tissue following treatment.
The aims with the present study were to collect further local and systemic
information on inflammatory responses of selected cytokines and goblet cell-associated
107

components following anthelmintic treatment with a single dose of moxidectin and
ivermectin in horses naturally infected with cyathostomin parasites to compare the effects
of a larvicidal versus nonlarvicidal product within the same drug class. This study
evaluated two post treatment time intervals (2 and 5 weeks) with emphasis on the role of
goblet cells and their potential involvement with worm expulsion. An additional aim was
to further evaluate the local and systemic pro- and anti-inflammatory gene expression
related to the larvae and to treatment.
5.2

Materials and methods
5.2.1 Study design
As stated in 4.2.1, this study was performed under the University of Kentucky’s

Institutional Animal Care and Use Committee, protocol number 2018-3134. Power
calculations for group sizes have previously been reported (Bellaw et al., 2018). Thirty-six
horses with naturally acquired cyathostomin infections, aged 2-5 years old, were kept on
pasture from August-October 2019. To allocate into groups, horses within a birth year were
grouped by sex and then ranked by decreasing magnitude of egg counts (Cringoli et al.,
2017). Then horses were blocked into groups of three and randomly allocated into each
group. Finally, the horses were then allocated into one of the two time intervals. Each group
contained a total of 12 horses, with 6 horses allocated to each of the two time intervals. All
study personnel were blinded to group allocations and treatments throughout the study.
On day -10, each horse was weighed on a certified livestock scale, and feces taken
for group allocation, as defined above. Horses in the moxidectin group received 0.4mg/kg
orally (Quest Plus, Zoetis Inc., Parsippany, NJ, USA), and horses in the ivermectin group
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received 0.2mg/kg ivermectin orally (Zimectrin Gold, Boehringer Ingelheim, Duluth, GA,
USA) on Day 0. The horses in the untreated control did not receive any treatment.
Six horses from each group were euthanized on days 14 and 15 (2 weeks post
treatment). Three horses from each group were necropsied each day to ensure equal
numbers of horses from each group were necropsied simultaneously. The rest of the 18
horses were kept on pasture until they were euthanized in the same manner as above, on
days 35 and 36 (5 weeks post treatment).
5.2.2 Sample collection
Weekly blood samples, starting at Day -10, were collected from all ponies
until euthanasia and placed into TempusTM blood RNA tubes (Applied BiosystemsTM,
Foster City, CA, USA) per the manufacturer’s instructions. The filled tubes were
vigorously shaken for 15-30 seconds and incubated at room temperature for 24 hours. The
blood samples were then placed at -20C until further processing.
As part of the necropsy procedure, tissue samples were taken with a 6mm biopsy
punch the CEC, VC, and DC, weighing 20-30mg. Tissue samples were placed directly into
RNALater (Life technologies, Grand Island, NY, USA), and left at room temperature for
24 hours and then placed at 4C until further processing.
5.2.3 Cytokine gene expression
5.2.3.1 RNA Isolation and reverse transcription
Total RNA was isolated from whole blood Tempus tube samples as
described by Page et al., 2017. Briefly, Samples were placed into 50mL tubes and washed
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with 3mL 1xPBS and centrifuged at 300g and 4C for 10 minutes. 600µl of Viral Lysis
buffer (Invitrogen, Carlsbad, CA, USA) was added and to each sample and vortexed to
suspend the pellet. RNA was extracted with Kingfisher Flex (Thermo Scientific, Waltham,
MA, USA) instrument and MagMax CORE Nucleic Acid Purification Kit (Applied
BiosystemsTM, Foster City, CA, USA). Samples were stored at -80°C until further use.
Tissue was processed similarly to the blood. Approximately 25mg of tissue
were lysed with 10µl proteinase K and 90µl proteinase K buffer from the MagMax CORE
Nucleic Acid Purification kit for 2h at 55C. The sample was then added to the 96 well
plate and processed according to manufacturer’s tissue extraction instructions, with using
the Kingfisher Flex tissue RNA program.
Reverse transcription of the samples was carried out similarly to Nielsen et al. 2015.
Briefly, RNA was quantified with a Biotek Epoch Biophotometer (Biotek, Winooski, VT,
USA). Reverse transcription reactions were carried out in an Applied Biosystems Veriti 96
well Thermal Cycler (Applied BiosystemsTM, Foster City, CA, USA), using 6µl Maxima
Reverse transcriptase (Thermo ScientificTM, Waltham, MA, USA), 4µl RNA, and10µl
nuclease free water. The cDNA was then diluted with 120µl RNase-free water (Qiagen,
Hilder, Germany). Samples were stored at -20°C until further use.
5.2.3.2

Quantitative Real Time Polymerase Chain Reaction

Gene expression was evaluated through quantitative RT-PCR assay for all blood
and tissue samples (Breathnach et al., 2006; Nielsen et al., 2015). Equine specific TaqMan
intron spanning primers and probes (Thermo-Fisher ScientificTM, Waltham, MA, USA)
were

used

for

this

study.

β-glucuronidase
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(β-GUS,

Ec03470630_m1),

IL-4

(Ec03468790_m1),

IL-5

(Ec03468691_m1),

IL-6

(Ec03468678_m1),

IL-10

(Ec03468647_m1),

IL-13

(Ec03470543_m1),

IL-17A

(Ec03470096_m1),

IFN-γ

(Ec03468606_m1), and TNF-α (Ec03467871_m1) were commercially available through
Thermo-Fisher Scientific and used in this study. Custom TaqMan® gene expression assays
were developed through Thermo-Fisher Scientific for IL-22 (AR9HJZX), MUC 2
(ARRWFPW), and RELM-β (AP47XR4). β-GUS was used as a housekeeping gene
Each reaction contained 5µl of SensiFASTTM Lo-Rox master-mix (Bioline,
London, UK), 0.5µl of 20x TaqMan assay for primers and probes of interest (assays-bydesign, Applied Biosystems), and 4.5µl of cDNA. Duplicate wells were prepared for each
sample and gene. QuantStudio 7 Flex Real-Time PCR System (Applied BiosystemsTM,
Foster City, CA, USA) was used to assess gene expression. LinRegPCR was used to adjust
qRT-PCR efficiencies (Ramakers et al., 2003). qRT-PCR data were normalized to the
housekeeping gene (β-GUS), and analyzed using the 2-∆∆CT method (Breathnach et al.,
2006; Livak and Schmittgen, 2001).
5.2.4 Statistical Analyses
Statistical analyses were carried out using SAS 9.4 (SAS Institute, Cary, NC, USA).
Mixed linear models were constructed for evaluating the effect of treatment group and days
post treatment on gene expression. The ‘glimmix procedure’ was used and ‘horse ID’ kept
as a random effect. ‘Group’, ‘day’, and ‘organ’ were kept as class variables. Models were
built to analyze each cytokine, with repeated measures taken into account for systemic
expression. The traditional forward and backward elimination of variables was used to
evaluate the influence of all parameters. Variables with P-values of 0.2 or below remained
in the model and the interaction between group and day was evaluated in all analyses (Lee
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and Koval, 1997). A ‘least square means’ analysis was used for a Tukey’s pairwise
comparison of categorical variables with p<0.05. A significance level of α=0.05 was used
for data interpretation. Figures and linear pairwise correlations were conducted through
JMP Pro 14 (SAS Institute, Cary, NC, USA), and a Pearson correlation coefficient
obtained. For the correlations, goblet cell hyperplasia s associated gene expression, and all
inflammatory cytokine expression were used as variables.
5.3

Results

5.3.1 1.1.1 Goblet cell-associated and anti-inflammatory cytokine gene expression
5.3.1.1

Gene expression in the intestinal tissue

There were no significant differences in the goblet cell-associated and antiinflammatory gene expressions between the treatment groups or among the 2 timepoints
within the intestinal tissue (p>0.05, Figure 5-1). IL-13 was elevated in the DC compared
to the CEC; whereas MUC2 expression was highest in the cecum (p=0.0246); however,
there were no other significant differences of genes within the organs (Figure 5-2). Finally,
IL-22 was positively associated with the number EL3 larvae (p=0.0418). Correlations
among cytokines in the tissue are presented in Table 6-5. Correlation between the genes
expressed in the intestinal tissues. Bold indicates significant correlations.
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Figure 5-1. Relative expression of goblet cell associated gene expression and antiinflammatory gene expression within the tissue at 2 and 5 weeks post treatment.
Upper and lower bounds of the boxes represent the upper and lower quartiles,
respectively.
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Figure 5-2. Relative quantities of expression of goblet cell associated and antiinflammatory genes within the organ tissues. Different letters denote significant
differences between organs. Upper and lower bounds of the boxes represent the
upper and lower quartiles, respectively. Abbreviations are as follows cecum (CEC),
vnetral colon (VC), and dorsal colon (DC).

5.3.1.2 Gene expression in the systemic circulation
In systemic circulation, there were no significant differences of goblet cell and
anti-inflammatory associated genes between the treatment groups (p>0.05). All genes
followed similar trends in systemic circulation, with 4 WPT as a significant timepoint
among all genes (p=0.0494). Regarding goblet cell gene expression over time, significant
differences were noted among the timepoints (p=0.0020, Figure 5-3). IL-10 expression was
low at 2,3, and 5 WPT compared to treatment and 4 WPT (p<0.001). IL-13 increased
slightly to 3 WPT, dropped significantly at 4 WPT, and then increased dramatically at 5
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WPT. IL-22 has similar trends to IL-13; however, it was significantly decreased at 2 and 4
WPT (p<0.001). MUC2 was highest at 2 WPT, lowest at 4 WPT, with a rebound at 5 WPT
(p<0.0001), whereas RELM- β was lowest at 2 WPT, highest at 4 WPT, with a significant
drop at 5 WPT (p=0.0494). Correlations between genes are listed in Table 6-6.

Figure 5-3. Relative quantitites of goblet cell associated gene expression in systemic
circulation over time. Different letters denote significant differences between
timepoints. Upper and lower bounds of the boxes represent the upper and lower
quartiles, respectively.
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5.3.2 Pro-inflammatory cytokine gene expression
5.3.2.1 Gene expression in the intestinal tissue
IFN-, had the highest expression in ivermectin treated horses compared to
moxidectin and the controls, and with the lowest expression in the moxidectin group
(p<0.001). It was also negatively associated with encysted larval burdens (p<0.001) and
expression was highest at 5 WPT compared to 2 WPT (p<0.001). Highest expression was
in the CEC, followed by VC, with the lowest in the DC (p=0.001). TNF- expression was
decreased in the two treatment groups, with moxidectin expressing the lowest level of
TNF- (p<0.001). Expression was highest in the VC compared to the cecum and DC, with
lowest expression in the DC (p<0.001). Comparing 2 versus 5 WPT, TNF- expression
decreased in the moxidectin group, remained similar in the ivermectin group, and increased
in the control group (p<0.001). Correlations between proinflammatory genes within the
tissues are listed in Table 6-6.
Other pro-inflammatory (IL-4, IL-5, IL-6) cytokine expression was negatively
associated with encysted larval burdens (p=0.0013). Expression of IL-5 was highest in the
cecum, followed by DC and then VC (p=0.0077). IL-17A, on the other hand, was highest
in the DC, compared to the CEC and VC (p=0.0340) and positively associated with MUC2
(p=0.0294).
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Figure 5-4. Relative quantities of expression of pro-inflammatory cytokine genes
within the tissues. Different letters denote significant differences between organs.
Upper and lower bounds of the boxes represent the upper and lower quartiles,
respectively. Abbreviations are cecum (CEC), ventral colon (VC), and dorsal colon
(DC).
5.3.2.2 Gene expression in systemic circulation
There were no significant differences of proinflammatory cytokine gene expression
in systemic circulation between groups (p>0.05). Proinflammatory cytokine gene
expression exhibited significant associations with other genes. IL-4 gene expression in
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systemic circulation was positively associated with IL-5, IFN-, but negatively associated
with IL-6, IL-10, MUC2, RELM- β, TNF-α, and encysted larval counts (p=0.0172).
Expression of IL-4, and IL-5 cytokines was highest at 4 WPT, and lowest at 0 and 1 WPT
post treatment (p=0.010). Across all groups, IL-6, IL-10, MUC2, RELM- β, TNF-α,
expression was lowest at 4 WPT, and then increased in expression at 5 WPT (p=0.0477,
Figure 5-5).). IL-6 gene expression was highest at treatment and 5 WPT, and lowest at 4
WPT (p=0.0321, Figure 5-5).
Interestingly, IFN- was negatively associated with EL3 counts (p=0.0167). IFN-
gene expression increased from treatment to 3 WPT, then dropped at 4 and 5 WPT, and
TNF-α followed a similar pattern (p=0.0224, Figure 5-5). Correlations between the
proinflammatory cytokine gene expression levels in systemic circulation are listed in Table
6-6.
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Figure 5-5. Relative gene expression of proinflammatory cytokines from treatment
to 5 WPT. Different letters denote significant differences between timepoints. Upper
and lower bounds of the boxes represent the upper and lower quartiles, respectively.
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5.4

Discussion
This is the first study to evaluate the local tissue gene expression to ivermectin

treatment. There was significant difference in the proinflammatory response between the
two treatment groups and between the untreated control horses. Within the tissues, both
treatment groups had considerably lower pro-inflammatory response, specifically with
regards to IFN- and TNF-α, compared to the untreated control group; however,
moxidectin treatment was associated with decreased expression when compared to
ivermectin treated horses. This may not be a direct effect of the treatment itself, but more
likely due to the removal of the luminal worms and some of the encysted stages within the
tissues, because we see the significant difference between the treatment groups and the
untreated control group.
Previously, we reported the decreased encysted larval burdens and GCH at the 5
WPT (Chapter 4). While it appears that a similar trend was followed in GCH gene
expression in this current study, it was not statistically significant within the tissues;
however, the expression of these GCH related genes within the systemic circulation was
significantly different among the timepoints. Also, at 4 WPT, there were several significant
spikes and drops in cytokine expression. For example, IL-4 and IL-10 significantly
increased, whereas MUC2 and Il-22 significantly decreased. It is possible that a significant
event occurred within the tissues, whether it be parasite maturation and excystment into
the lumen, further worm expulsion from the lumen, but this remains unknown. It may also
suggest that GCH decreased briefly within the tissues, and therefore there may have been
a decrease in worm burden or worm expulsion. This will be evaluated in more depth when
the luminal counts of cyathostomins become available. The GCH markers and the
120

relationship they exhibit with each other, GCH, and worm burdens is similar to what we
previously reported (Chapter 2); however, this study reports a significant pro-inflammatory
response to the worms present in the tissues, which was previously reported by other
studies (Davidson et al., 2005b, 2002).
Finally, we further describe the differences between the large intestinal organs,
which we previously reported in Chapters 2, 3, and 4. The organs clearly produce a
different response to encysted larvae and treatment. For example, the DC appears to
express higher pro-inflammatory cytokine levels (such as IL-6), which may lead to the
lower mucosal larval burdens observed; whereas, the CEC had a greater GCH response,
but not pro-inflammatory response, and may indicate higher turnover of larvae in this
organ. However, this requires further investigation into the mechanisms behind the
infection.
In regard to systemic circulation, IL-22 and MUC2, and RELM-ß may be potential
markers for epithelial cell turnover, goblet cells, and worm burden, and they appear to be
from spillover from the intestines, as previously described; however, as with all other
markers, there are other potential factors that may influence these in systemic circulation,
such as coinfections with bacteria, other inflammatory insults or diseases that may increase
goblet cell turnover within the host ( Nielsen et al., 2015; Steuer et al., 2018).
In conclusion, this is the first study to evaluate the local tissue gene expression to
ivermectin treatment. While we noted that ivermectin treated horses had a few increased
proinflammatory markers, this was not likely due to the compound itself, but that higher
worm burdens (specifically mucosal encysted larval burden) elicit a greater pro-
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inflammatory response. GCH and its related genes also appear to be associated with worm
burdens and remain an area of interest and further exploration.
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CHAPTER 6. DISCUSSION
6.1

Introduction to the discussion
The studies presented herein form a small bridge over the current knowledge gaps

concerning the host parasite interaction between horses and cyathostomins, and the effects
of anthelmintic treatment. The discussion is presented with an overview of major findings,
differences between the treatment classes, larvicidal versus nonlarvicidal treatment, the
differences between timepoints, systemic responses, and goblet cells and their potential
role.
6.2

Overview of major findings
The work presented herein reports the first studies to evaluate local and systemic

inflammatory and goblet cell responses to cyathostomin infections and anthelmintic
treatment at 2 and 5 weeks post treatment (WPT). The unique design in the studies allows
for a comparison across all four chapters. Age range, time of year, group size, blinding,
allocation, and treatment protocol, as well as necropsy techniques were kept equivalent to
allow comparisons between the two studies; however, the first study used a population of
ponies and the second study used horses, which may account for some differences.
Overall, reducing the number of encysted larvae and/or adult worms reduced the
proinflammatory response in the horses and ponies, as presented in Chapters 2-5. FBZ may
lead to a slightly increased proinflammatory cytokine response compared to the
macrocyclic lactones (MLs), specifically moxidectin (MOX); however, MOX had higher
inflammatory cell populations (see section 6.3). Whereas the nonlarvicidal ivermectin
(IVM) led to a greater proinflammatory response than MOX (see section 6.4), but there
was no difference in the inflammatory cell populations between the MLs.
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Another unique aspect of these studies is the two post treatment necropsy
timepoints. This is the first time that IVM, MOX, and FBZ have been evaluated at an
interval greater than 2 WPT. This was originally performed to capture the egg reappearance
period of the anthelmintics and to study changes in the worm populations (Bellaw et al.,
2018). However, this allowed us to evaluate the local immunological reaction and study
what may happen with the phenomenon of larval excystment, adult worm expulsion, and
general parasite turnover. We found that, even without anthelmintic treatment
administered, there was a significant decrease in mucosal worm burdens from 2 to 5 WPT,
whereas luminal worm burdens increased from 2 to 5 WPT in the first study. This will be
discussed in greater length in 6.5
Another aspect of this study is the novel comparison of the CEC, VC, and DC in
both studies. We found that the organs produced significantly different inflammatory and
immunologic responses, which correlated with their different worm burdens, which will be
discussed further in section 6.6.
Finally, the investigation of Goblet cells and their potential role in cyathostomin
infections and horses was a main component of this dissertation. Goblet cell hyperplasia
(GCH) has been reported with infections and disease since 1978 (Ogbourne, 1978);
however, the exact role remains unclear. GCH and mucins were positively associated with
treatments and encysted and luminal cyathostomin burdens in both studies and IVM treated
horses had higher GCH responses, which will be discussed further in 6.7.
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6.3

Benzimidazole versus macrocyclic lactone treatments and their immunologic
effects
The limited differences in the inflammatory cell response described in the current

work was attributed to the encysted and luminal worm burden present within the host,
rather than the parasites that were removed and the potential reaction that may cause. The
inflammatory cell populations primarily surround the larvae remaining in the intestinal wall
and is associated with the larvae rather than focal areas without larvae present or a diffuse
response (Chapters 2 and 3). This is also supported by the lack of differences between our
treatment groups, and the control group, in general, expressing a greater inflammatory
response. In both studies, IVM, MOX and FBZ exhibit different larvicidal efficacy;
however, some larvae remain, regardless of treatment (Bellaw et al., 2018). At maximum,
74.6% of larvae were removed from the tissues, with values ranging from 0-74.8% at the
2 and 5 WPT timepoints (Bellaw et al., 2018, Chapter 3). Therefore, a large proportion of
the worms were left behind in all groups, allowing for continued stimulation of the immune
system in all horses. However, if removal were to cause a greater response with dying and
decaying larvae, there would be greater expression of proinflammatory cytokines in those
with the highest percentage of removal, which was not found (Chapters 3 and 5). While
the low level of efficacy is due to drug resistance of the parasites to FBZ (Bellaw et a;.,
2018), the exact mechanism for MOX is not currently known; however, the variable
efficacy is well described (Table 1-3). The groups with higher larval counts had a higher
proinflammatory response than those that do not (Chapters 2-4).
The inflammatory cell populations and reactions reported herein contradict the
findings by Steinbach et al. and Nielsen et al. Briefly, Steinbach et al. noted a greater
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inflammatory cell response in the FBZ treated group compared to the MOX group; whereas
Nielsen et al. described a subtle response to MOX (Nielsen et al., 2015; Steinbach et al.,
2006). It was suggested that this was due to of the reduced FBZ larvicidal efficacy, which
contrasts Steinbach et al. (2006), who reported adequate efficacy of FBZ, although the
exact efficacy was not reported. Our study observed increased macrophage and T cell
counts following MOX treatment compared to the FBZ treated group; however, overall the
two products had similar larvicidal efficacies, which contradicts the suggestion that the
lack of inflammatory response to FBZ could be due to reduced efficacy. When taking into
account the mechanisms of action of the anthelmintics, FBZ and MOX act different upon
the parasites, which was discussed in 1.2.4. In other hosts, such as in as dogs with
Dirofilaria immitis infections, the use of MLs inhibits E/S secretions of the microfilaria
(L1 larvae) and therefore allows the host immune response to detect and remove the larvae
(Vatta et al., 2014; Zahner et al., 1997). In comparison, FBZ kills the parasites, and then
allows for removal by the host immune system. This allows for different antigenic
stimulation and reaction to the parasites within the host tissues.
6.4

Larvicidal versus non-larvicidal treatments and the immunologic effects
The larvicidal efficacies of moxidectin and ivermectin were within the ranges

previously reported (Bellaw et al., 2018; Eysker et al., 1997, 1992; Love, 1995; Monahan
et al., 1998, 1996; Xiao et al., 1994). The hypothesis that more larvae decrease the
inflammatory response is rejected by Chapters 4 and 5, comparing IVM and MOX.
Ivermectin treated horses had an increased proinflammatory response compared to MOX.
GCH related genes had no significant differences within the tissues between the groups
and timepoints. IFN- γ expression was highest in IVM treated horses, lowest in MOX,
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suggesting that a reduction in parasite burden results in a lower proinflammatory response.
Proinflammatory cytokine expression significantly associated with encysted larval
burdens. It is also reported that ivermectin (or nonlarvicidal treatments) is implicated in
disease (Reid et al., 1995), which is not true of other strongylid parasites and host systems.
This indicates a unique case within cyathostomins and how the parasites response to
treatment and interact with the host immune system.
6.5

The differences between the timepoints: larvae and worm turnover revisited
Due to the longer follow-up times post treatment, these studies (Chapters 2 and 4)

detected an interesting phenomenon within the encysted burdens, where they were highest
at 2 WPT and lowest at 5 WPT across all groups. Originally, this was attributed to a lab
error; however, given the repeatability, it appears that another influence may be occurring.
One potential factor is seasonality and worm turnover. Once per or twice per year, the adult
worms will die and be replaced by the immature worms. This developed from the notion
that at the adults live for 270-470 days within the host, and that L4s were more numerous
in the spring than summer, and again in the fall (Gibson, 1953; Matheison, 1964;
Ogbourne, 1975; Smith, 1976a). While the previous authors believed that this occurs in the
spring before the grazing season, this turnover may actually occur in the fall, after the
grazing season, which is supported by these data, that they found high numbers of L4s in
the fall, and that larval cyathostominosis occurs in the late fall/winter-early spring (Gibson,
1953; Ogbourne, 1975; Peregrine et al., 2006; Reid et al., 1995; Schäfer et al., 2019; Smith,
1976a). Treatment inducing development of the encysted worms is also supported by the
luminal counts from Chapter 2 where luminal counts, especially luminal L4s in the
treatment groups increased from 2 to 5 WPT; and encysted larval counts in Chapter 2 and
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Chapter 4 which decreased from 2 to 5 WPT (Gibson, 1953; Matheison, 1964; Ogbourne,
1975; Smith, 1976a). However, since this was also noted in the treatment group, this may
also indicate the seasonality of the parasite as well.
The limited differences in the inflammatory cell response described in the current
work were thought to be from the encysted and luminal worm burden present within the
host, rather than the parasites that were removed and the potential reaction that may cause.
Higher eosinophil, macrophage, and other inflammatory cell scores were associated with
later stage and degenerative larvae and all of these inflammatory cell scores were higher at
2 WPT across all groups in Chapter 2, and neutrophils in Chapter 3.
6.6

Organs and tissue responses: are all large intestinal compartments created equal
The control group had the highest response within the tissues. The best explanation

for this phenomenon is that higher numbers of cyathostomins, both encysted and luminal,
increase the inflammatory response, which was opposite of what we hypothesized. The
findings that there is a different response between the organs also makes logical sense.
Organs responded differently in both studies, histologically and in cytokine
expression. Overall, it appears that a higher proinflammatory response occurs in the DC,
and the CEC has a higher goblet cell reaction (Chapters 3 and 5). This is consistent with
lower worm burdens in the DC, followed by CEC, then VC, reported in this study. And
may attribute to the DC’s lower encysted and luminal worm burdens, or the different
species composition of the DC may contribute to a greater inflammatory response;
however, this is consistent with previous studies (Chapman et al., 2003; Davidson et al.,
2002; Hogan et al., 2006; Maizels et al., 2012; Reinemeyer et al., 1986). Why the organs
have different worm species compositions, worm burdens, and mucosal reactions remains
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an area of interest and pursuit when trying to understand the infection dynamics and
possible disease processes.
Finally, we know that horses develop a level of immunity to cyathostomins, as
represented by older (>4 years) horses having decreased egg counts compared to young
horses and foals (1-3 years of age, and <1, respectively) (Klei and Chapman, 1999).
Younger horses have higher encysted larval counts and differing responses in tissues,
including in the DC, than older horses (Collobert-Laugier et al., 2002), illustrating a
difference that occurs within this tissues of horses, and that the immunological and
inflammatory response changes over time (as described in 1.3.2.1.1). The proinflammatory
response likely triggers worm expulsion from the tissues, creating an inhospitable
environment for most worm populations and these are areas of future exploration.
6.7

Systemic responses
Overall, the studies reported herein support the hypothesis of “spillover” previously

presented (Nielsen et al., 2015), where the systemic cytokine and gene expression and
differences between these may result from what is occurring in the large intestine. We
measured goblet cell genes in systemic circulation that correlated positively with the tissue
expression of these genes (Chapters 3 and 5). Systemically, while there were differences
among timepoints and these correlated with tissue expression of all genes, many of these
were not statistically significant (Chapters 3 and 5). This is likely due to the overall
complexity of cytokines and their functions, and many crossovers with the immune system
and its signaling. What is of note is those involved with the mucosal response, such as
MUC2, RELM-β, and IL-22 directly correlated with the tissue expression, though at lower
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levels, and were identified in systemic circulation, indicating potential markers for
monitoring goblet cell function within horses.
6.8

Goblet cells and their role
Goblet cell hyperplasia positively correlated with the luminal counts. This is

interesting, as it may have implicated the role of GCH in larval excystment into the lumen
of the large intestines and/or expulsion of the worms from the host. In other host models,
GCH, along with increased mucin and product production allow for decreasing the
interaction between the epithelium and parasites, and along with increased contractility,
allow expulsion from the host (Hasnain et al., 2013a; Murgia et al., 2017; Rousseau et al.,
2011). The parasites in these rodent models investigated do not have an encysted stage
within the large intestine, as cyathostomins do. The triggering of excystment, and the
potential involvement of goblet cells and their mucins to aid this process is therefore
unknown. These reactions remain an area of future interest.
In this study, we observed a potential spillover of gene expression from the large
intestinal tissues, including those relating to GCH.. In other species it was found that IL22, GCH, MUC2 (among other mucins), and RELM-β expression were directly related to
worm burden and worm expulsion, with higher expression and concentrations associated
with greater worm burden and worm expulsion (Chen et al., 2012; Hansson, 2012; Hasnain
et al., 2010; Maizels et al., 2012). IL-10 was inversely correlated with worm expulsion in
studies as well (Hasnain et al., 2013b). We made similar findings, where GCH and related
genes appeared to be related to worm turnover; however, higher GCH scores were
associated with lower mucosal scores, but higher luminal counts. This may suggest that the
luminal counts have a greater and more direct effect than the mucosal counts on GCH, or
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vice versa. However, IL-10 and IL-22 may directly be correlated with mucosal worm
burdens, as illustrated in Chapter 3. This may indicate a role in the encysted worms
modulating the host immune system.
These studies found that a greater GCH response occurred with the untreated
controls compared to the treatments and was lowest in the MOX group. This suggests that
greater encysted burdens may be implicated in GCH and worm turnover; however, this is
the opposite of the previous study (Chapter 2). This suggests that the encysted larval stages
do not have a role in GCH, or vice versa; however, it remains a possibility that GCH may
play a crucial role in larval excystment and luminal worm turnover may or vice versa. It is
unsure what relationships luminal counts will have with GCH in this study; however, it is
likely that luminal counts will be significantly associated with GCH, which is supported
by other host parasite models (Hasnain et al., 2010; Turner et al., 2013). Without luminal
counts, it is hard to determine the role of GCH; however, it is likely that the excystment
into or expulsion out of the lumen of the large intestine is influenced by GCH or vice versa
in cyathostomin infections.
Goblet cells and their products are key components of the host inflammatory
response, as illustrated here and in other host/parasite interactions (Hasnain et al., 2010;
Herbert et al., 2009; Mishra et al., 2007; Rodrigues et al., 2018). The goblet cells directly
relate to luminal and encysted cyathostomin burdens in horses; however, other
coinfections, such as with bacteria, may play a significant role. Treatment does not directly
modulate GCH in horses; however, treatment may modulate GCH by modulating worm
burdens.
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6.9

Concurrent parasitic infections
One other component of this study to discuss is concurrent A. perfoliata infections

in these horses. There were no tapeworms found in the treated horses; however, the control
horses had A. perfoliata burdens in both studies (unpublished data); however, they were
not correlated with any of the inflammatory responses in these horses. The
histopathological samples were not taken near the ileocecal valve in these horses, where
the primary A. perfoliata burdens reside. However, it is possible that these burdens would
have an influence as seen in another study where epithelial proliferation, GCH, and
cytokine responses were higher in A. perfoliata infections (Lawson et al., 2019). However,
these studies did not account for cyathostomin infections and samples were collected
directly at the site of A. perfoliata attachment and did not compare to those tissues within
the same host (Lawson et al., 2019). Therefore, it is unlikely that A. perfoliata coinfections
contributed significantly to the findings of our studies.

6.10 In vivo versus in vitro
This work is a first step toward identifying the effect of anthelmintic treatment on
the inflammatory response and the role of goblet cells in cyathostomin infection. Further
evaluations would require in vitro cultivation of large intestinal mucosa (or an alternative
tissue representation), exposure of other equivalent cell lines (as in (Lawson et al., 2019)
inoculated with cyathostomins, or different study approaches in vivo. As previously
described in 0, there is a lack of success culturing the parasitic stages of cyathostomins.
Furthermore, immune and cell population responses can change rapidly, within minutes to
hours of insult, making it challenging to identify appropriate timepoints for in vivo studies.
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In place of the two- and five-week timepoints used in the current studies, an alternative
would be more immediate timepoints, such as one, two, and seven days post treatment.
However, this may introduce the ethical challenges concerning the amount of horses
needing to be euthanized to achieve statistical significance. Another option would be
cannulation of horses for repeated biopsies; while the stomach, ileum, and CEC have been
readily cannulated (Austbø and Volden, 2006; Meyer and Klingeberg-Kraus, 2002; Peloso
et al., 1994; Williams et al., 2018); the colons, due to location, size, and risk of infection
and peritonitis pose a unique set of concerns. The large intestinal cannulation of horses also
poses an ethical potential with the increased risk of infection, disease, and rupture. In one
study with long term dual cecal and ileal cannulation, 63% of subjects were euthanized due
to intestinal herniation (Williams et al., 2018). Cannulations would also not allow for large
subsampling, or sampling of multiple known areas. Overall, cannulation would be a
potential option; however, there are great ethical, financial, and study design
considerations beforehand.
One facet to consider is in vitro studies, as well as using other host models. As
mentioned, being able to culture the parasitic stages of cyathostomins is not currently
possible in vitro (Brianti et al., 2009; Klei and Chapman, 1999). As far as using other host
models, cyathostomins have not been established in other hosts, including
immunosuppressed rodent models (Klei and Chapman, 1999). Using other host/parasite
models, there are no other strongylid parasites or other laboratory animal models that
include a hypobiotic developmental phase in the large intestine; making exact correlations
difficult at this time.
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6.11 Overall conclusion
Healthy horses with large encysted and luminal burdens that receive a treatment do
not have a greater proinflammatory response than horses that do not receive treatment.
Larvicidal treatments have a lower proinflammatory response than non-larvicidal treatment
in healthy horses. The greater the encysted cyathostomin burden within a horse, the greater
proinflammatory response they will have. In horses, goblet cells have an association with
cyathostomin infections. Systemically, it appears that spillover of goblet cell related genes
occurs and may be a future area of monitoring the goblet cell reaction in horses.
•

H1: Equids that receive anthelmintic treatment will have a lower local and
systemic inflammatory responses than equids that do not- Reject; the
untreated control horses had higher pro-inflammatory responses in the
tissues and there was no difference in systemic circulation

•

H2: MLs will have a greater inflammatory response than BZs due to their
higher efficacy and removal of larger encysted and luminal cyathostomin
burdens- Reject, efficacies and responses were similar

•

H3: Larvicidal treatment will incite a greater inflammatory response from
encysted and luminal worm die-off than non-larvicidal treatment- Reject,
proinflammatory responses were highest in the controls, which had the
greatest encysted and luminal worm burdens

•

H4: A greater cyathostomin burden, both mucosal and luminal, will decrease
the proinflammatory response- Reject; the opposite was reported in these
studies
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•

H5: Encysted cyathostomins will be able to potentiate an anti-inflammatory
response- Accept; There seems to be an association between the antiinflammatory markers and encysted burden

•

H6: Local inflammatory responses to treatment will appear in systemic
circulation as “spillover”- Accept; There seems to be some spillover of
genes related to GCH in systemic circulation
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APPENDICES

APPENDIX 1. Supplemental Figures and Tables for Chapter 2

Figure 6-1. Box-whisker plots representing inflammatory cell scores (0 = none; 1 =
1-5 cell layers, mild inflammation or fibrosis; 2 = 6-15 cell layers, moderate
inflammation or fibrosis; or 3 = >15 cell layers, severe inflammation or fibrosis),
larval numbers, and lesion size (mm) in the three treatment groups at 2 and 5 weeks
post treatment. Upper and lower bounds of the box represent the upper and lower
quartile, respectively. The diamond represents the mean of the observations and the
whiskers represent the minimum and maximum observations per group. a) Fibrous
Connective Tissue Scores, b) L3 larvae in lamina propria, c) L4 larvae in in the
mucosa, d) total mucosal length, e) goblet cell hyperplasia scores, f) B lymphocyte
scores (IHC), g) T lymphocyte scores (IHC), h) macrophage scores (IHC), i)
neutrophil scores, j) macrophage scores, k) eosinophil scores, l) lymphocyte scores.
The fenbendazole group contains 6 animal at both 2 and 5 weeks post treatment.,
the Moxidectin group contains 7 individuals at 2 weeks post treatment and 5
animals at 5 weeks post treatment, and the control group contains 5 animals at 2
weeks post treatment and 7 animals at 5 weeks post treatment.

Table 6-1. Average mean larval counts per 50mm. Ventral Colon is abbreviated VC
and Dorsal Colon is abbreviated DC.
Group

Weeks
Post
Treatment

Organ

Intact
L3 in
lamina
propria

Degenerative
L3 in lamina
propria

Intact L3
in
submucosa

Degenerative
L3 in
submucosa

Intact
L3 in
glands

Intact
L4 in
mucosa

Degenerative
L4 in mucosa

Intact L4
in
submucosa

Degenerative
L4 in
submucosa

Control

2

Cecum

2.25

0

0

0

0.16

3.90

0

1.48

0

DC

0.19

0

0

0

0

0

0

0

0

5

Fenbendazole

2

5

Moxidectin

2

5

VC

1.62

0

0

0

0

1.30

0

0.16

0

Cecum

1.87

0

0

0

0.42

0.53

0

0.11

0.12

DC

0.34

0

0

0

0

0.13

0

0

0

VC

0.77

0

0

0

0

0.12

0

0.22

0

Cecum

0.78

0

0

0

0.12

1.02

0

0

0.37

DC

0

0

0

0

0

0

0

0

0

VC

0.51

0

0

0

0.12

0.62

0

0

0

Cecum

0.46

0

0

0

0

0.61

0

0

0

DC

0

0

0

0

0

0

0

0

0

VC

0.64

0

0

0

0

0

0

0.35

0

Cecum

0.49

0

0.31

0

0

1.36

0

0

0

DC

0.19

0

0.11

0

0

0

0

0

0

VC

0.61

0

0

0

0

1.22

0

0

0

Cecum

1.03

0

0.13

0

0

0.29

0

0.71

0

DC

0

0

0

0

0

0

0

0

0

VC

0.87

0

0

0.3

0

0.41

0

0.14

0
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Table 6-2. Supplemental Table 2. Average histopathology scores for statistically
significant variables Ventral Colon is abbreviated VC and Dorsal Colon is
abbreviated DC.
Weeks Post
Organ
Eosinophil
Goblet
Fibrous
Treatment
Scores
Cell
Connective Tissue
Scores
Scores
2

5

2

5

2

5

Cecum

1

0.33

1.06

VC

1.3

0.5

1.2

DC

-

0

-

Cecum

1.14

0.33

1

VC

0.43

0.5

1.14

DC

-

0

-

Cecum

1.42

0.14

1.11

VC

0.88

0.29

1

DC

0.67

0

1

Cecum

0.72

0.6

1.17

VC

1

1

1

DC

0

0.2

-

Cecum

0.83

0.4

1.23

VC

0.37

0.6

1.16

DC

0.33

0.6

1.33

Cecum

0.4

0.71

1

VC

0.85

1.14

1.08

DC

1

0.29

1
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Figure 6-2. Box-whisker plots of the natural log of the relative quantities (RQ) of
mRNA expression of selected cytokines in the blood over time, as shown by
treatment groups and study week the blood was drawn (-1-5). Upper and lower
bounds of the boxes represent the upper and lower quartiles, respectively. -1 is the
pretreatment blood sample. 0 is treatment, followed by 1, 2, 3, 4, and 5 weeks post
treatment of IL-10 and IL-13

Figure 6-3. Box-whisker plots of the natural log of the relative quantities (RQ) of
mRNA expression of goblet cell-associated genes in the blood over time, as shown by
treatment groups and week of blood collection. Upper and lower bounds of the
boxes represent the upper and lower quartiles, respectively. -1 is the pretreatment
blood sample. 0 is treatment week, followed by 1, 2, 3, 4, and 5 weeks post
treatment. WPT (weeks post treatment).
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Figure 6-4. Box-whisker plots of the natural log of the relative quantities (RQ) of
circulating mRNA for pro-inflammatory cytokines in the blood over time, as shown
by treatment groups and week of blood collection. Upper and lower bounds of the
boxes represent the upper and lower quartiles, respectively. -1 is the pretreatment
blood sample. 0 is treatment week, followed by 1, 2, 3, 4, and 5 weeks post
treatment. WPT (weeks post treatment).
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Figure 6-5. Box-whisker plots of the natural log of the relative quantities (RQ) of
circulating mRNA for pro-inflammatory cytokines in the blood over time, as shown
by treatment groups and week of blood collection. Upper and lower bounds of the
boxes represent the upper and lower quartiles, respectively. -1 is the pretreatment
blood sample. 0 is treatment week, followed by 1, 2, 3, 4, and 5 weeks post
treatment. WPT (weeks post treatment) for TNF- α, IFN- γ, and IL-17A.
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Table 6-3. Pairwise correlations between the different genes within the blood. The r
values are presented to illustrate linear relationships. BOLD values indicate
statistical significance.

IL-10
IL-13
IL-17A
IL-22
IL-4
IL-5
IL-6
MUC2
RELM-β

0.1103

IL-13

0.3337

0.3337

IL-17A

0.1678

0.3604

-0.1139

IL-22

0.2622

0.1314

0.2285

-0.1402

IL-4

-0.0148

0.0629

-0.1875

0.1312

IL-5

0.2216

0.0893

0.3951

0.4076

IL-6

0.9893

0.1594

0.3381

-0.1213

MUC2

0.2554

0.9831

0.1673

0.3602

-0.0989

RELM-β

-0.1079

-0.2486

0.1582

0.2725

0.5483

TNF-α

-0.0101

0.2468

-0.0388

0.4339

0.2054

-0.0289

0.2192

-0.2631

0.5056

0.3639

0.1999

0.9861

-0.2349
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Table 6-4. Pairwise correlations between the different genes within the tissue. The r
values are presented to illustrate linear relationships. BOLD values indicate
statistical significance.

IFN-γ
IL-10
IL-13
IL-22
IL-4
IL-5
IL-6
MUC2
RELM-β

0.745

IL-10

0.8297

0.8626

IL-13

0.7443

0.7251

0.4903

IL-22

0.5004

0.8216

0.5862

0.5087

IL-4

0.3209

0.4855

0.438

0.5441

IL-55

0.6434

0.9612

0.8364

0.8122

IL-6

0.9843

0.7738

0.7631

0.5962

MUC2

0.4833

0.9215

0.782

0.7844

0.6703

RELM- β

0.3814

0.2358

0.5587

0.7963

0.0267

TNF- α

0.16

0.4988

0.4026

-0.0179

0.645

0.392

0.755

0.2197

0.0828

0.4179

0.7619

0.9417

-0.1278
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Table 6-5. Correlation between the genes expressed in the intestinal tissues. Bold
indicates significant correlations.
IFN- γ

IL-10

IL-13

IL17A

IL-22

IL-4

IL-5

IL-6

MUC2

RELM- β

TNF- α

0.926

0.041

0.945

0.611

0.986

0.989

0.525

0.761

0.752

0.982

0.859

0.941

0.877

0.862

0.941

0.761

0.898

0.902

0.935

0.921

0.793

0.782

0.487

0.556

0.789

0.801

0.842

0.904

0.945

0.955

0.889

0.923

0.930

0.946

0.606

0.691

0.861

0.999

0.992

0.784

0.935

0.667

0.691

0.705

0.983

0.631

0.788

0.784

0.962

0.865

0.865

0.260

0.998

0.881

IL-10
IL-13
IL-17A
IL-22
IL-4
IL-5
IL-6
MUC2
RELM- β

0.882

Table 6-6. Correlation between genes expressed in systemic circulation. Bold
indicates significant correlations.
IFN- γ
IL-10
IL-13
IL-17A
IL-22
IL-4
IL-5
IL-6
MUC2
RELM-β

MUC2

RELM-β

TNF- α

0.368

0.508

0.142

0.098

0.003

-0.228

0.093

0.348

-0.244

-0.092

0.105

0.035

-0.195

0.034

0.997

0.092

0.230

-0.060

-0.004

0.146

0.049

-0.167

0.124

0.010

0.0357

0.137

0.984

-0.007

-0.483

-0.230

-0.028

-0.112

0.412

0.613

0.036

0.100

0.472

0.087

0.029

0.444

-0.149

IL-10

IL-13

IL-17A

IL-22

IL-4

IL-5

IL-6

0.077

0.115

0.312

0.101

0.062

0.815

-0.270

0.030

-0.243

0.527

0.068

0.984
-0.008

0.075
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